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ABSTRACT 
THE ZUCKER RAT AS A MODEL OF OBESITY-HYPERTENSION 
by Ryan Morrison 
 
 
Hypertension is a serious health problem that affects approximately 1 in 4 American 
adults.  Most cases are diagnosed as essential hypertension, meaning that the exact cause 
is unknown.  In most patients, however, excess weight is a major contributory factor to 
the development of essential hypertension.  The role of obesity in promoting 
hypertension is now well documented and has become the foundation for an entire field 
of research known alternately as obesity-hypertension, obesity-induced hypertension, or 
obesity-associated hypertension.  In this field, rapid advances are being made in our 
understanding of how obesity and hypertension are linked.  A plethora of related risk 
factors, mediators, and pathways have now been identified and described through the use 
of a variety of animal models.  Nonetheless, the relationships between these factors and 
the extents to which they promote obesity-hypertension are often poorly understood.  
Unscrambling the various cardiovascular and metabolic determinants of obesity-
hypertension remains a persistent problem because both obesity and hypertension 
typically exhibit polygenic etiologies and diet-dependent dynamics in humans.  The 
judicious use of appropriate animal models promises to be an important tool in this quest.  
In addition, animal models are vital platforms for designing and evaluating approaches to 
the treatment of obesity-hypertension.  One model of particular interest is the obese 
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Zucker rat, which develops extreme obesity but only develops slight, if any, 
hypertension.  The primary objective of the research in this dissertation was to determine 
whether obese rats were more sensitive to experimental conditions known to induce 
hypertension than age- and gender-matched lean controls. Lean and obese Zucker rats 
were subjected to two experimental protocols that are known to induce hypertension in 
other rodent strains:  (1) the administration of deoxycorticosterone-acetate and salt to 
uninephrectomized rats and (2) feeding rats a moderately high fat, salt-supplemented 
(MHF-SS) diet.  In each case, the obese Zucker rat was found to be more susceptible to 
the development of hypertension.  A second goal of this research was to ascertain a 
possible mechanism through which the MHF-SS diet might induce hypertension in obese 
Zucker rats.  In this regard, dysfunction of the nitric oxide system, particularly in the 
kidney, was implicated in the pathogenesis of the MHF-SS diet in obese Zucker rats.  In 
conclusion, this research suggests that the obese Zucker rat is labile with regard to blood 
pressure and that renal nitric oxide dysfunction may promote hypertension when obese 
Zucker rats are fed a moderately high fat, high salt diet. 
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PREFACE 
 
 The primary research in this dissertation is composed of two published, peer-
reviewed manuscripts (chapters 2 and 3) and a manuscript that will be submitted for 
publication (chapter 4).  These manuscripts are summarized and expanded on in the 
conclusions (chapter 5).  In addition, sections of the literature review (chapter 1) may 
eventually be revised and submitted for publication.  The literature review establishes the 
importance of animal models to the study of obesity-hypertension and briefly highlights 
the advances being made with popular models.  Chapters 2 and 3 describe the 
development of the deoxycorticosterone acetate-salt treated obese Zucker rat model, 
while chapter 4 discusses a model using a moderately high fat, salt-supplemented diet in 
the obese Zucker rat.   
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CHAPTER I 
 
Literature Review 
 
 
Introduction 
Obesity is now recognized by the World Health Organization as a critical global health 
problem (WHO, 2000).  Recently, the prevalence of obesity has skyrocketed in the 
United States and other industrialized countries.  According to the National Health and 
Nutrition Examination Studies (NHANES), obesity levels in the United States grew from 
about 14% to nearly 31% from 1980 to 2000 (Flegal et al., 2002).  Despite increased 
awareness, the prevalence of obesity has continued to rise and we now face a worldwide 
epidemic of obesity-related health problems.   To make matters worse, children are being 
increasingly affected (Sorof et al., 2004) and clinical interventions that promote 
population-wide weight control have been generally ineffective.  Consequently, pressure 
to develop our understanding of obesity and how it contributes to other disease states is 
quickly mounting. 
 
Because the prevalence of obesity has risen so rapidly, it seems clear that environmental 
factors are ushering in this change.  In particular, the widespread adoption of high fat 
diets (Lissner and Heitmann, 1995) and sedentary lifestyles have been implicated 
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(Williamson et al., 1993).   This precipitating effect of lifestyle changes on the increasing 
incidence of obesity, however, does not rule out the potential of a strong genetic 
component in the development of obesity.  To the contrary, an environment of nutrient 
excess may allow for the full expression of obesity promoting genes that were previously 
masked when nutrients were less abundant.  It is likely that genes that participate in 
determining energy balance, metabolism, and some behavioral traits are cooperating with 
environmental changes to ultimately regulate, or fail to regulate, weight gain.  In much 
the same way that an individual’s complex genetic background determines susceptibility 
to obesity, genetic background determines the susceptibility of obese individuals to a 
number of obesity-associated comorbidities as well. 
 
Obesity has been defined in various ways.  Clinicians in the United States have 
historically used height-weight based mortality data from the Metropolitan Life Insurance 
Company to define obesity.  Currently, the body mass index (BMI) is the most widely 
accepted standard (Kushner, 1993).  BMI is defined as weight in kg divided by height in 
meters, squared.  Since cardiovascular risks begin to increase substantially when BMI 
increases above 25, a BMI greater than 25 is typically used to define clinically 
overweight individuals.  Nearly two thirds of the US population (64%) is overweight by 
this definition (Flegal et al., 2002).  Admittedly, this method often inappropriately 
classifies muscular individuals as clinically overweight.  Consequently, methods that 
assess adipose tissue mass and distribution more accurately than BMI may constitute the 
future standard.  Regardless of how obesity is defined, there is abundant evidence to 
indicate that excessive body weight is associated with elevated mortality rates.  The 
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magnitude of this obesity-associated risk is further influenced by age, gender, and the 
pattern of fat distribution (Kushner, 1993).  For example, abdominal obesity appears to 
disproportionately increase the risk of developing certain comorbidities such as 
cardiovascular disease (Sundquist et al., 2001). 
 
Paralleling the rise in obesity, the prevalence of hypertension has also increased in the 
last decade.  Roughly 29% of the US population over the age of 18 and 65% of the US 
population over the age of 60 is hypertensive based on the criteria of a blood pressure in 
excess of 140/90 mmHg or use of hypertensive medications (Hajjar and Kotchen, 2003).  
The rise in the prevalence of obesity is a chief factor in the increased incidence of 
hypertension (Care, 2005), which can lead to stroke, heart failure, kidney failure, and 
other serious health complications. 
 
Obesity and hypertension are common in developed countries, but the rate of co-
occurrence of these two disorders in a single individual cannot be explained by mere 
random coincidence (Hsueh and Buchanan, 1994).  Hypertension occurs in 25% to 50% 
of obese individuals, which is a significantly higher prevalence than in the general 
population (Bell, 1990).  According to risk estimates from the Framingham Heart Study, 
obesity is linked to about 75% of male and about 65% of female cases of hypertension 
(Davy and Hall, 2004; Garrison et al., 1987).  Even in patients who are not obese, modest 
changes in body weight have been positively correlated with blood pressure, although 
individuals vary in their susceptibility to this effect (Davy and Hall, 2004). 
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Genetic factors such as ethnicity can determine whether obesity will lead to hypertension.  
Pima Indians have a high rate of obesity, but a low rate of hypertension (Weyer et al., 
2000).  In addition, hypertension is more prevalent in black men than white men, despite 
comparable levels of obesity (Abate et al., 2001).  Similarly, genetically obese animals 
vary in their predisposition to hypertension depending on the specific strain being 
studied.  The variation may depend on the specific mechanisms underlying the 
development of obesity (Mark et al., 1999) or on blood pressure control mechanisms.   
 
Although the connection between obesity and hypertension was recognized nearly a 
century ago (Antic et al., 2003), we are still at a relatively early stage in achieving the 
goal of fully understanding the complex neural, cardiovascular, and hormonal pathways 
that lead from obesity to hypertension.  The pace of advance is accelerating, however, in 
the wake of a growing multitude of manipulations and mutations available in animals for 
modeling and investigating human obesity-associated hypertension.  Even now, existing 
animal models have provided a foundation of knowledge and hold the potential to 
unscramble many of the cardiovascular and metabolic determinants of obesity-
hypertension.  Additionally, novel animal models are rapidly emerging as valuable tools 
in the quest to discover and evaluate the genetic mutations and pathophysiological 
pathways that contribute to complex cardiovascular disorders such as obesity-
hypertension.  
 
In humans, both obesity per se and hypertension per se are typically caused by complex 
interactions of multiple environmental and genetic factors, resulting in a multiplicity of 
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etiologies for each disease.  Thus, neither obesity-hypertension nor its components 
(obesity and essential hypertension) can be completely explained by a single 
pathophysiological mechanism.  More likely, a plethora of convoluted pathways with 
varying levels of significance will need to be elucidated in order to fully comprehend the 
role of obesity in promoting hypertension.  
 
It has been previously reported that the establishment of cause-and-effect relations in the 
field of obesity-hypertension is hindered by a shortage of suitable animal models, which, 
if available, would allow monitoring of the sequence of renal, cardiovascular, and 
endocrinological functional changes during the development of obesity (Hall et al., 
1993).   Meaningful advances in the field of obesity-hypertension depend upon the 
development of an assortment of animal models that have characteristics in common with 
those observed in obesity-hypertension in humans.  These advances may be facilitated by 
sophisticated techniques that are designed to evaluate complex networks of gene 
interactions, such as the integrated genomics approach that was proposed by Schadt et al. 
(2005).  Alternative statistical models such as factor analysis or structural equation 
modeling might also be required to unravel the complex network of pathways than link 
obesity to hypertension (Chan et al., 2002).  Meta-analyses, which are performed by 
synthesizing research results from previously separate, yet related, studies, can now 
compile past and current research from diverse model-specific studies.  As our 
knowledge of the mechanistic basis of obesity-hypertension advances, new potential 
targets for treatment may emerge. 
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Some of the factors that have been implicated in obesity-hypertension are represented in 
the disorder known alternately as the insulin resistance syndrome, the metabolic 
(cardiovascular) syndrome (X), and/or the “deadly quartet.”  Although this syndrome has 
been defined in various ways, obesity and hypertension are central and persistent 
elements.  Junquero et al. (2005) recently summarized the varying syndrome definitions 
as “the clustering of moderate troubles of glucose, lipid metabolism, body weight, 
hypertension and vascular inflammation.”  The most commonly used clinical definition 
seems to be The National Cholesterol Education Program’s Adult Treatment Panel III 
report (ATP III), which lists the characteristics of the metabolic syndrome as abdominal 
obesity , atherogenic dyslipidemia, elevated blood pressure, insulin resistance, a 
proinflammatory state, and a prothrombotic state.  This clustering is well documented in 
humans (Aizawa et al., 2005) and is present in many of the animal models of obesity-
hypertension, illustrating both the multifactorial nature of obesity-hypertension and the 
highly conserved nature of these dysfunctional metabolic relationships in mammals.  
While obesity may play the most pivotal role in promoting hypertension, it is believed 
that each of the aforementioned clustering elements can play a role in the advancement of 
blood pressure dysregulation (Morse et al., 2005).  Thus, models that overexpress or lack 
these clustering elements may be invaluable for discerning how their association with 
obesity may play a role in promoting hypertension. 
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Models of Obesity-hypertension: An Overview 
An ideal animal model for a disease “closely represents most or all of its 
pathophysiological characteristics (Tschop and Heiman, 2001).”  Although a number of 
factors have been implicated, the pathophysiological characteristics of obesity-
hypertension have not been clearly defined yet.  Moreover, no single animal model is 
universally representative of obesity-hypertension, although some models exhibit many 
of the aforementioned clustering factors.  Hence, nearly any animal that expresses obesity 
and hypertension may serve as a viable research tool, even if obesity and hypertension 
are not coupled.  At this juncture, it appears that the most practical approach to the study 
of obesity-hypertension would be to use a wide range of species/models. 
 
Fortunately, experimental obesity has now been produced in a large assortment of rodents 
using dietary manipulation, chemical and surgical treatments, selective breeding, and/or 
genetic manipulation (Tschop and Heiman, 2001).  Many, but not all, of these models 
spontaneously develop hypertension as they age and gain weight.  Such models are 
naturally suited for the study of obesity-hypertension.  In addition, many of the remaining 
models of obesity may still be developed into models of obesity-hypertension by 
applying additional hypertensive influences.  For example, results from our laboratory 
and others indicate that obese rodents may be more vulnerable to the hypertensive 
influence of salt than their lean counterparts (Dobrian et al., 2003; Morrison et al., 2002; 
Radin et al., 2003).  This association between obesity and salt-sensitivity of blood 
pressure is also evident in humans and other animals, although the exact mechanism 
linking these conditions is not fully understood (Rocchini, 2000).    
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Besides salt, several other environmental stimuli may be useful as tools for developing 
models of obesity-hypertension.  For example, high protein intake has been positively 
associated with changes in blood pressure in humans (Suter et al., 2002).  Alternatively, 
reducing the metabolic rate by elevating ambient temperatures or increasing caloric 
intake with palatable diets can directly promote obesity (Tschop and Heiman, 2001), 
thereby indirectly promoting hypertension.  Diets that are high in fat and refined 
carbohydrates have been shown to promote both obesity and hypertension in inbred rats 
(Barnard et al., 1993).  Moreover, saturated fats and refined carbohydrates have been 
associated with salt retention and hypertension in humans (Preuss, 1997).  Fortunately, 
researchers now benefit from the increasing commercial availability of standardized and 
purified diets with adaptable macronutrient compositions. 
 
Numerous factors determine the most appropriate model selection for an investigator:  
research scope and objectives, institutional resources, cultural biases regarding species of 
animals, and individual investigators’ preferences.  In the US, rodents have been the 
dominant species adopted for research (FBR, 2006; Jacoby, 1998).  They feature low 
breeding and maintenance costs (Fitzgerald, 1983), easy handling and feeding, short 
lifespans, wide commercial availability, minimal cultural backlash, and a well-understood 
physiology.  For that reason, this overview focuses primarily on rodents.  However, it 
should be noted that excellent models of obesity-hypertension have been developed using 
dogs (Rocchini et al., 1987) and rabbits (Carroll et al., 1996) and may be developed from 
other animals as well.    
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When using an animal model, careful consideration has to be given to factors such as age 
and gender when designing experiments and interpreting data.  For example, it is known 
that gender can have a significant effect on susceptibility to blood pressure elevation in 
rodents; however, the exact nature of the effect varies across strains (Herrera and Ruiz-
Opazo, 2005).  Susceptibility to hypertension is also influenced by age in rodents, which 
generally have lifespans of about two years.  A good time to initiate many studies may be 
at about 100 days, when rats cease to gain lean mass, but when fat mass may still be 
accrued (Tschop and Heiman, 2001)  Aging in rats may result in increased susceptibility 
to hypertension (Ren et al., 1999).  This is consistent with human observations, where the 
prevalence of hypertension and obesity have been shown to increase with age (Bray and 
Gray, 1988; Kannel et al., 1967).  This association between obesity and hypertension in 
humans, however, tends to weakens with advanced age (Van Itallie, 1985). 
 
Another important general consideration with respect to rodent models is the breeding 
source and method.  Inbred and outbred strains that conform to established standards of 
breeding are widely available from reputable commercial vendors.  Outbred strains have 
greater genetic diversity, making them well suited as a model for pharmacological studies 
that attempt to understand how a drug will behave in a diverse population.  Inbred 
animals have a high occurrence rate of potentially harmful and confounding homozygous 
recessive mutations.  Furthermore, inbred animals are subject to genetic homeostasis 
(Hartl, 2000), a paradoxical effect which leads to a counter intuitive elevated variance 
with respect to many of the measurable quantitative characteristics in inbred rodents 
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(Phelan and Austad, 1994).  Despite this drawback, inbred animals still have distinct 
advantages. They allow reliable comparison of data across laboratories because the 
population is genomically stable and can be repeatedly accessed.  The fixed genotypes of 
inbred animals also allow investigators to isolate the influence of environment from 
unknown genetic variations that may play a role in determining phenotype.  Perhaps most 
importantly, these models can be rapidly developed and are an invaluable tool for 
functional genomics, as demonstrated by Svenson et al. (2003).   
 
Model Categories 
Rodents that develop obesity as a result of a single gene mutation can still be outbred to 
maintain genetic diversity throughout the rest of their genetic background (e.g. the obese 
Zucker rat).  These outbred monogenic models of obesity provide an excellent source for 
well-controlled, reproducible analysis of specific pathophysiologic links between obesity 
and hypertension.  In addition, they provide a unique opportunity to study the individual 
contributions of specific metabolic dysfunctions in obesity-hypertension and are 
invaluable for testing translational clinical advances that relate to rare monogenic forms 
of obesity-hypertension. 
 
Rodent models with hypertension resulting from polygenic obesity are in some ways the 
most relevant for studying human obesity-hypertension.  In particular, such models are 
well-suited for the investigation of generalized therapeutic approaches to obesity-
hypertension.  As demonstrated by Tsukahara et al. (2004), intercrossing strains with 
specific “clustered” phenotypes that are associated with hypertension is also a useful tool 
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for understanding polygenic hypertension.  Conversely, this study indicated that, in some 
cases, the development of obesity and the development of hypertension are not 
genetically associated in some inbred mouse models of obesity-hypertension.  
 
In order to simplify discussion of the strengths and weaknesses of individual models, they 
are classified in this section according to the following schema, which was loosely based 
on the system used by Sun and Zhang to review animal models of hypertension per se 
(Sun and Zhang, 2005).  The models of obesity-hypertension are categorized as genetic, 
dietary, or treatment models, depending on the methods used to produce the model and 
the underlying basis of obesity-hypertension.  These categories are given original 
definitions so that all existing models of obesity-hypertension fall into a specific 
category.  Of course, it may be possible to develop a hybrid model that does not fit neatly 
into any single category.  In addition, models of obesity-hypertension based on 
environmental factors such as temperature change or stress induction have not been 
developed, so they are not given a category, although it may be possible to develop such 
a model. 
 
Genetic Models 
Genetic models of obesity-hypertension spontaneously develop both obesity and 
hypertension on standard laboratory diets as a result of their genetic makeup.  Such 
models can be produced with targeted mutagenesis, transgenics, or selective breeding of 
spontaneous mutants.  These are the most popular and widely used models, probably 
because they generally require the least technical input, the role of confounding factors is 
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minimized, and research can be focused on the mechanisms that explain how specific 
mutations give rise to obesity and hypertension.  Currently, the obesity component in 
most of the genetic models is based on disorders of leptin signaling and transduction.  
Prominent examples of genetic models with leptin dysfunction include the fa/fa rat, ZSF1 
rat, SHROB rat, and ob/ob mouse.   
The Spontaneously Hypertensive Obese Rat (SHROB) 
The spontaneously hypertensive obese rat (SHROB; Koletsky) was developed by Richard 
Koletsky at Case Western Reserve Medical center after he discovered a spontaneous 
mutation, designated corpulent (cp), that results in a shortened and completely 
nonfunctional leptin receptor.  The cp mutation was crossed onto the spontaneously 
hypertensive rat (SHR/N) background, resulting in the SHROB (Greenhouse, 1990).   In 
the SHROB, hypertension and obesity are caused by independent genetic mutations.  
Studies showing that SHROBs are not any more hypertensive than SHR/Ns suggest that 
genetically determined hypertension is not exacerbated by genetically determined obesity 
in this model (Ernsberger et al., 1999b).  Since the SHROBs also exhibit severe 
hyperinsulinemia and insulin resistance, this blood pressure data also suggests insulin 
resistance does not contribute to hypertension in this model (Friedman et al., 1997).  The 
decoupling of obesity and hypertension in the SHROB may preclude its use as a model 
for identifying specific metabolic factors that link obesity to hypertension.  Nevertheless, 
the SHROB has proven to be quite useful as a tool for investigating pharmacological 
approaches  for the treatment of obesity-hypertension (Ernsberger et al., 1997; Ernsberger 
et al., 1999a; Friedman et al., 1998; Koletsky et al., 2003; Mukaddam-Daher et al., 2003) 
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and is considered by some to be a good model for metabolic syndrome X (Ernsberger et 
al., 1999a; Velliquette and Ernsberger, 2003).   
Obese Zucker Rat (OZR) 
The obese Zucker rat (OZR) was discovered by Drs. Theodore and Lois Zucker after a 
spontaneous mutation, designated fatty (fa), occurred in an outbred stock of their rats 
(Greenhouse, 1990).  The mutation, located in the gene for the leptin receptor (Takaya et 
al., 1996), is autosomal recessively inherited.  Severe obesity results because the rat, 
which has a diminished ability to respond to leptin, becomes hyperphagic. 
 
Conflicting data exists as to whether the obese Zucker rat is actually hypertensive.  Some 
investigators have reported that the OZR is not hypertensive relative to lean Zucker rats 
(Bunag and Barringer, 1988; Morgan et al., 1995; Pamidimukkala and Jandhyala, 1996; 
Pawloski et al., 1992; Reddy and Kotchen, 1992), whereas other investigators have 
indicated that the OZR is hypertensive, although the degree of hypertension reported is 
generally mild (Alonso-Galicia et al., 1996; Ambrozy et al., 1991; Carlson et al., 2000; 
Kurtz et al., 1989; Maher et al., 1995; Turner et al., 1995).  The OZR appears to be 
slightly salt-sensitive (Carlson et al., 2000; Reddy and Kotchen, 1992) and experiments 
in our laboratory have shown that this sensitivity can be exacerbated by DOCA and 
uninephrectomy (Morrison et al., 2002) or a high fat diet (not submitted for publication 
yet).  The OZR also develops marked insulin resistance, hyperinsulinemia, 
hypertriglyceridemia, and hypercholesterolemia.  In addition, the renin-angiotensin 
system may play a role in mediating hypertension in this model (Alonso-Galicia et al., 
1996).  
 14
Wistar Fatty (WFR) 
The fatty gene that spontaneously arose in obese Zucker rats was backcrossed onto 
outbred Wistar rats by Dr. Hitoshi Ikeda at Takeda Chemical Industries in Osaka, Japan 
(Greenhouse, 1990).  The Wistar fatty rat (WFR) becomes spontaneously hypertensive, 
hyperglycemic, and hyperinsulinemic in association with increased sympathetic nervous 
system activity (Suzuki et al., 1999; Yamakawa et al., 1995).  In addition, the WFR also 
exhibits salt sensitivity of blood pressure (Hayashida et al., 2001) and a shifted pressure 
natriuresis curve (Suzuki et al., 1996).  Unfortunately, the American colony of WFRs at 
Indiana University Medical Center was lost (Greenhouse, 1990) and it seems that 
research on this strain is limited primarily to Japan. 
11-β-Hydroxysteroid Dehydrogenase type 1 (11βHSD1) transgenic mice 
In humans, 11-beta-hydroxysteroid dehydrogenase type 1 (11βHSD1) converts inactive 
cortisone to biologically active cortisol (Dotsch and Rascher, 2002).  In rodents, 
11βHSD1 converts inactive 11-dehydrocorticosterone to active corticosterone, the major 
rodent glucocorticoid  (Draper and Stewart, 2005).  Thus, the main function of 11βHSD1 
is to convert specific inactive glucocorticoid metabolites to glucocorticoid metabolites 
that can activate the glucocorticoid receptor (Draper and Stewart, 2005).  Glucocorticoids 
play an important role in fat metabolism and in the distribution of adipose tissue.   
 
11βHSD1 has been linked to obesity and insulin resistance in humans (Draper and 
Stewart, 2005).  Jeffrey Flier’s group in Boston recently developed a strain of transgenic 
mice that overexpress 11βHSD1.  These mice developed visceral obesity and exhibited 
other symptoms of the metabolic syndrome (Masuzaki et al., 2001).  They also developed 
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salt-sensitive hypertension that may be mediated by the renin-angiotensin system 
(Masuzaki et al., 2003).   
New Zealand Obese Mice (NZO) 
New Zealand obese (NZO) mice were developed by selectively breeding obese agouti 
mice for 5 generations (Giesen et al., 2003).  The NZO spontaneously develops obesity 
and hypertension, as well as insulin resistance, hypertriglyceridemia, and 
hypercholesterolemia (Ortlepp et al., 2000).  Diabetes develops by six to twelve months 
in the NZO due to a loss of pancreatic β-cells (Plum et al., 2002).  Moreover, high fat 
feeding accelerates or worsens many of the pathophysiological symptoms that are 
exhibited by the NZO, suggesting that the NZO may be useful in assessing the role of 
diet in the development of obesity-hypertension (Giesen et al., 2003; Plum et al., 2002). 
 
Dietary Models 
There are a number of commercially available diets that can produce obesity in certain 
susceptible rodents.  In turn, these obesity-prone rodents may develop hypertension over 
a period of time.  Dietary models develop obesity as a result of polygenic susceptibility to 
obesity and hypertension upon exposure to dietary manipulation.  Thus, genetics plays a 
role in determining obesity and hypertension in these models, although this confounding 
factor may be controlled somewhat by using inbred animals.  Animals that gain excessive 
weight on the special diets are considered to be genetically susceptible, whereas those 
which are resistant to weight gain are considered to be genetically resistant (Levin et al., 
1987).  Dietary models are perhaps the most relevant type of model because they closely 
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resemble the etiology of human obesity-hypertension.  In particular, high fat feeding 
produces obesity that “closely mimics the metabolic, neurohumoral, renal, and 
cardiovascular changes observed in obese humans” (Hall et al., 2003b).  Dietary models 
have the potential to become a powerful tool for elucidating the complex interplay 
between genetics and environment that determines whether obesity produces 
hypertension.  In addition, these models can be used to discover previously unconsidered 
obesity-hypertension genes and markers and to investigate dietary and therapeutic 
approaches for the treatment of obesity-hypertension.  Examples of dietary models of 
obesity-hypertension include the purified moderately high fat diet used by Dobrian et al. 
(2000) and the high-fat refined carbohydrate diets used by Barnard, Roberts and 
associates (Barnard et al., 1993).  These models have thus far tended to show the 
importance of oxidative stress (Dobrian et al., 2001; Roberts et al., 2005) and nitric oxide 
dysfunction (Dobrian et al., 2001; Roberts et al., 2003) as a factor in obesity-
hypertension.  
 
Treatment Models 
Treatment models use surgical manipulations or chemical injections to produce or 
exacerbate obesity and/or hypertension.  Of course, genetic background still plays an 
important role in determining susceptibility, just as in dietary models.  Hypertension can 
be experimentally induced using a wide array of surgical and chemical methods, 
including clipping the renal arteries, wrapping the kidneys, injecting salt retaining agents 
into uninephrectomized rats (e.g DOCA), and by administering NOS inhibiting agents 
such (e.g. L-NAME) (Sun and Zhang, 2005).  
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Animal models of obesity have been developed using a variety of chemical and surgical 
means.  For example, obesity can be produced by radiofrequency, electrolytically, or 
surgical lesions the paraventricular or the ventromedial nuclei of the hypothalamus.  
Also, a number of chemical agents, including colchicine, kainic acid, ibotenic acid, 
monosodium glutamate, piperidyl mustard, goldthioglucose, and monosodium glutamate 
can be administered to produce obesity (Tschop and Heiman, 2001).   These methods 
have been used primarily to study obesity per se but it may be possible to apply these 
techniques with different strains and diets to develop new models of obesity-
hypertension.  
DOCA-salt treated obese Zucker rat (DST-OZR) 
Our lab has recently used DOCA-salt treatment of obese Zucker rats (DST-OZR) to 
determine whether obesity increases the sensitivity of rats to experimentally induced 
hypertension.  DST-OZRs become severely hypertensive within a few weeks of initiating 
treatment, whereas genetically lean Zucker rats were far less affected (Morrison et al., 
2002).  Furthermore, OZRs developed more extensive glomerulosclerotic kidney damage 
than LZRs, with or without DOCA-salt treatment (Morrison et al., 2005).  This is 
consistent with reports that classify obesity as a risk factor for nephropathy, especially 
focal segmental glomerulosclerosis (Cohen, 1999).  Additionally, obesity is known to 
aggravate renal dysfunction in humans (Sasatomi et al., 2001).  With respect to this, we 
have observed significant proteinuria in the DST-OZR, indicating that functional damage 
to the kidney takes place in these animals (Morrison et al., 2005).  It is currently unclear, 
 18
however, whether these changes are caused by obesity itself or by the associated 
hypertension and hyperlipidemia (Sasatomi et al., 2001).   
 
The DST-OZR model is described in chapters 2 and 3.  This model effectively illustrates 
the susceptibility of obese rats to hypertensive pressures.  It may also be well suited for 
studying how obesity affects the rate of end organ damage in malignant hypertensive 
states (Morrison et al., 2005).   
 19
Monosodium Glutamate Injected Hypertensive Rats 
Monosodium glutamate (MSG) has been used to create models of obesity-hypertension 
from known models of hypertension per se, including the SHR (van den Buuse et al., 
1985) and the 1-kidney, 1-clip hypertensive (1K1C) rat (Correa and Saavedra, 1992).  
MSG is injected into the bodies of neonatal rats, where it travels to the hypothalamus and 
overexcites neurons to the point of cell death, causing an obesity producing lesion.   
Despite the independence of obesity and hypertension in the MSG injected SHR, this 
model still displays at least a weak relationship between obesity and hypertension.  For 
example, blood pressure is lower in MSG-treated SHR than in control SHR (van den 
Buuse et al., 1985), whereas it may not be changed by MSG treatment in 1K1C rats 
(Correa and Saavedra, 1992).   Interestingly, MSG  seems to increase susceptibility to 
weight gain in the SHR, but this effect does not appear to be associated with changes in 
leptin (Iwase et al., 2000).  The vast majority of research with this model has focused on 
the effects of MSG-induced obesity on the SHR (Hambley et al., 1987; Iwase et al., 2000; 
Iwase et al., 1998; Mosqueda-Garcia et al., 1986; Ross et al., 1993; van den Buuse et al., 
1985).   
 
Proposed Mechanisms of Obesity-hypertension 
According to Bray, obesity-hypertension is caused by metabolic changes that are 
associated with excessive fat cell growth (Bray, 2004).  These changes may produce 
hypertensive pressures directly as in the case of obesity-associated sympathetic nervous 
system activation or they may reduce the subject’s ability to handle other hypertensive 
pressures (e.g. obesity-associated endothelial dysfunction).  The latter case suggests that 
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models of hypertension generated by making genetically hypertensive rats obese can be 
useful even when hypertension is not induced by obesity per se (e.g. DST-OZR, 
SHROB).   
 
Studies in animal models have led to the proposal of a wide array of mechanisms that 
may explain obesity-hypertension.  These proposed mechanisms will be briefly reviewed 
in this section.  Since obese hypertensives do not always exhibit all of the clustering 
factors that are implicated in these mechanisms, the explanatory power of any individual 
mechanism is limited.  Moreover, multiple obesity-associated abnormalities may be 
required in an individual before hypertension can ultimately develop.  
Hyperinsulinemia/Insulin Resistance 
Hyperinsulinemia has been repeatedly cited as the primary metabolic derangement 
underlying the association between obesity and hypertension (Ljutic and Korsic, 1993; 
Zemel, 1995).  Obesity promotes insulin resistance, which is widely believed to cause 
compensatory hyperinsulinemia in an effort to sustain euglycemia (Olefsky et al., 1982).  
Studies indicate that insulin resistance and compensatory hyperinsulinemia promote 
increased sympathetic nervous system activity, renin-angiotensin system activity, and 
vascular smooth muscle cell proliferation (Imazu, 2002).  Both insulin resistance per se 
and hyperinsulinemia have been blamed for increasing peripheral vascular resistance and 
blood pressure (Zemel, 1995).  Insulin resistance per se may lead to hypertension because 
diminished insulin-stimulated Ca2+  ATPase activity retards the extrusion of  Ca2+ from 
vascular smooth muscle cells (Rocchini, 1991; Zemel et al., 1992).  Also, 
hyperinsulinemia may promote hypervolemia and high blood pressures by directly 
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inducing renal sodium retention and elevating neural sympathetic output (Ljutic and 
Korsic, 1993; Rowe et al., 1981; Zemel, 1995).  On the other hand, results of other 
studies suggest a very different role for insulin.  For example, there is substantial 
evidence to indicate insulin is actually a vasodilator (Zemel, 1995).  Insulin has been 
reported to promote NO production and have antihypertensive effects in Zucker diabetic 
rats (Kawaguchi et al., 2001). 
 
Recently, attention has shifted away from the notion that diminished insulin action on the 
vascular endothelium can explain hypertension.  One reason is that mice lacking insulin 
receptors in the vascular endothelium have reduced blood pressures, even on a high-salt 
diet (Nandi et al., 2004).  Hall et al. (2003) have argued that the kidney is the primary 
long-term controller of blood pressure in obesity-hypertension, and attention has turned 
to the direct sodium retaining effects of insulin on the kidney.  The mechanism for this 
direct effect is not known, but insulin appears to increase sodium reabsorption in the 
distal tubule and decrease it in the proximal tubule (Stenvinkel et al., 1992).  Overall, the 
net effect of insulin is to promote sodium reabsorption and salt-sensitivity of blood 
pressure (Sechi, 1999).  Nevertheless, studies by Hall et al. (1993; 1992) suggest that the 
effects of insulin may be insufficient to produce chronic hypertension.  
Hyperleptinemia/Selective Leptin Resistance 
The fact that obese Koletsky and Zucker rats become hypertensive, despite a reduced 
ability or complete inability to respond to leptin, suggests that leptin is not required for 
obesity and hypertension to associate.  Nonetheless, there is growing evidence that leptin 
may function as a pathophysiological link between obesity and hypertension (Mukherjee 
 22
et al., 2006).  For example, transgenic mice that overexpress leptin have increased blood 
pressure relative to wild-type controls, despite having a lower body weight (Aizawa-Abe 
et al., 2000). 
 
Leptin is an appetite-regulating cytokine that is secreted from white adipose tissue in 
proportion to adipose tissue mass (Considine, 2005).  As a result, the plasma 
concentration of leptin is elevated distinctly in obese humans (Considine et al., 1996) and 
rats (Tulipano et al., 2004).  Substantial evidence from rodents indicates that leptin 
chronically activates the sympathetic nervous system (SNS) and increases blood pressure 
(Correia et al., 2001).  Chronic hypertension that is induced by leptin can be completely 
abolished by adrenergic blockade, indicating that the hypertensive actions of leptin are 
mediated by adrenergic activation (Carlyle et al., 2002).  In addition, leptin may also 
promote hypertension by increasing reactive oxygen species and upregulating endothelin-
1 production  (Luo et al., 2005).  Just as with insulin, though, leptin triggers counteracting 
hypotensive mechanisms which obfuscate its overall effect on blood pressure.  Leptin 
induces endothelium-dependent vasorelaxation  (Kimura et al., 2000; Lembo et al., 2000) 
and stimulates natriuresis (Jackson and Li, 1997; Villarreal et al., 1998).  Leptin also 
appears to elevate NO metabolites in the plasma, suggesting that its hypotensive actions 
may be NO dependent (Beltowski et al., 2002; Fruhbeck, 1999).   
 
Selective leptin resistance has been suggested as the causative factor for metabolic and 
cardiovascular dysfunctions associated with obesity, but the mechanisms that lead to this 
resistance are still unknown (Ren, 2004).  If tissue resistances to leptin are specific for its 
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hypotensive actions but not its sympathoexcitatory actions, then leptin could potentially 
induce hypertension.  In this regard, Rahmouni et al. (2005) have demonstrated that 
obese mice are resistant to the metabolic effects of leptin, while the stimulatory effect of 
leptin on renal sympathetic nervous activity is still preserved. 
Sympathetic nervous system 
It has been hypothesized that obesity may activate the sympathetic nervous system 
(SNS), a prohypertensive influence, in order to reduce or prevent further weight gain 
(Landsberg, 1992).  This seems like a plausible method by which the body could expend 
excess energy and thereby diminish fat accumulation.  As attractive as this hypothesis is, 
it has not been consistently supported by reports of SNS activity in obesity (Hsueh and 
Buchanan, 1994; Young and Macdonald, 1992).  Substantial evidence now exists 
supporting several opposing views: (1)  individuals develop obesity as a result of 
dysfunctionally lowered SNS activity, (2) SNS activity is increased to compensate for 
obesity (promoting hypertension) and (3) SNS activity is not changed in obese 
individuals (Young and Macdonald, 1992).  The discrepancies may be due to how and 
where SNS activity is assessed because there is considerable heterogeneity in 
sympathetic outputs to different organs (Hall et al., 2003a).  Hall et al. (2003a) believe 
that renal sympathetic activity, which has been shown to increase in obese subjects, is the 
primary pathway by which sympathetic nervous activity leads to chronic hypertension.  
Esler, however, has shown that increased renal sympathetic activity is not sufficient to 
produce hypertension in obese patients (Esler, 2000).  Still yet, increased sympathetic 
activity may be required in conjunction with other sodium retaining derangements in 
order for chronic hypertension to develop (Esler, 2000).  In conclusion, the effect of 
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obesity on the SNS varies considerably for reasons that are not clear, even though leptin 
and insulin, which are both elevated in obesity, apparently stimulate the SNS. 
Nitric Oxide (NO) 
Nitric oxide (NO) function plays at least two important roles in blood pressure regulation.  
First, NO has a well known role in endothelial regulation of vascular tone.  Disturbance 
of this physiological role could result in increased peripheral resistance, which is 
characteristic of all known forms of human and experimental hypertension (Kunes et al., 
2004).  Secondly, NO helps maintain sodium and water balance by acting as a key 
signaling molecule in pressure natriuresis, a key long term determinant of blood pressure  
(Evans et al., 2005).  The exact role of nitric oxide in mediating pressure natriuresis, as 
well as other aspects of pressure natriuresis, is still poorly understood (Evans et al., 
2005). 
 
NO metabolism may be dysregulated by metabolic factors associated with obesity, 
including leptin resistance and insulin resistance.  Studies have shown that NO 
production is increased by both leptin (Beltowski et al., 2002) and insulin (Steinberg et 
al., 1994) through the activation of phosphatidylinositol 3-kinase (Kim et al., 2000; Zeng 
et al., 2000).  In insulin and leptin resistant states, however, leptin and insulin may be 
incapable of producing this effect (Jiang et al., 1999).   Thus, selective insulin and leptin 
resistance might increase susceptibility to hypertension by inhibiting NO production but 
not the sympathoexcitatory actions of insulin and leptin.  There is now extensive 
evidence indicating that the SNS and NO are typically well balanced counterparts of 
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blood pressure regulation and that this balance is altered in experimental hypertension 
(Kunes et al., 2004).  
 
Obesity is also associated with oxidative stress, which may be due to extended 
postprandial hyperlipidemia and/or hyperglycemia (Dandona et al., 2001).  Obese 
humans have increased levels of oxidative stress and this is ameliorated by diet restriction 
and weight loss (Dandona et al., 2001).  Oxidative stress can lead to increased 
deactivation of NO, which may promote hypertension (Kunes et al., 2004).  
Kidney Compression 
Another mechanism which may explain obesity-hypertension is obesity-induced kidney 
compression that results in increased intrarenal pressure (Hall et al., 1998).  This 
compression may be produced by intra-abdominal pressure increases (Bloomfield et al., 
2000) and kidney encapsulation by retroperitoneal adipose tissue (Hall et al., 2002).  In 
addition, obesity might also exacerbate kidney compression by promoting extracellular 
matrix expansion (Henegar et al., 2001; Kasiske et al., 1985).  If the loops of Henle and 
vasa recta are compressed by mounting intrarenal fluid hydrostatic tissue pressure, then 
tubular water and sodium reabsorption could be increased (Hall et al., 2002).  This might 
explain why abdominal obesity bears a high relative risk for hypertension, but it does not 
account for the rapid increase in arterial pressure that occurs with weight gain (Hall et al., 
2003a).   
Renin-Angiotensin System (RAS) 
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Some components of the renin-angiotensin system are noticeably activated in obese 
individuals, despite its association with sodium retention and plasma volume expansion.  
Plasma aldosterone, angiotensinogen, angiotensin-converting enzyme activity, and 
plasma renin activity have all been reported to be elevated in obesity-hypertension (Hall 
et al., 2002; Sharma et al., 2002).  A role for the RAS is further supported by studies that 
show angiotensin II antagonists and angiotensin-converting enzyme inhibitors blunt 
sodium retention, plasma volume expansion, and blood pressure elevation in obese dogs 
and humans (Reisin et al., 1997; Rocchini, 2000). 
Sodium Retention 
According to Borst and Borst-de Geus, “The blood pressure will be maintained at the 
exact level required for the maintenance of sodium balance (Borst and Borst-de Geus, 
1963).”  Extensive evidence now indicates that sodium is at least partially responsible for 
producing hypertension (Altun and Arici, 2006), particularly when obesity is present 
(Antic et al., 2003).  The underlying mechanisms for this phenomenon, however, have 
not been fully elucidated.  Sodium retention leads to an expansion of extracellular and 
blood fluid volumes, which, in turn leads to an increase in blood pressure.  As described 
earlier, numerous factors that are commonly found in obesity may promote sodium 
retention by amplifying renal tubular sodium reabsorption.  These factors include kidney 
compression, RAS activation, and leptin-, insulin-, or free fatty acid-induced SNS 
activation (Antic et al., 2003; Wofford and Hall, 2004).  If obesity were to cause a 
chronic increase in tubular sodium reabsorption, then the compensatory mechanism, 
known as pressure natriuresis, would be activated to prevent infinite volume expansion.   
In normal situations, high salt intake leads to only very slight, if any, blood volume 
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expansion because of pressure natriuresis (Faber, 1996).  Thus, pressure natriuresis can 
normally raise sodium excretion enough to offset sodium intake with only slight increases 
in blood pressure.  It is unclear how the blood pressure elevations are transduced into 
changes in renal sodium excretion, but they probably lead to the inhibition of tubular 
sodium reabsorption because glomerular filtration rate and renal plasma flow are 
autoregulated to remain constant over a wide range of blood pressures (Evans et al., 
2005).  One possible explanation for obesity-hypertension is that pressure natriuresis is 
impaired so that higher blood pressures are required to increase sodium excretion 
sufficiently to eliminate any given level of sodium intake (Hall, 2003).  Other aspects of 
renal function might also contribute to obesity-hypertension.  For example, renal 
autoregulation may not be completely functional in obese subjects  as suggested by 
reports that the glomerular filtration rate is increased in obesity (Hall et al., 2001).   
Renal Injury 
There is substantial evidence suggesting that obesity significantly increases the risk for 
renal failure, perhaps more so than hypertension (Kincaid-Smith, 2004).  For example, 
studies have indicated that obese patients are significantly more likely to develop 
proteinuria and a progressive loss of renal function (Morales et al., 2003).  In one study, 
92% of clinically obese patients who underwent unilateral nephrectomy developed 
proteinuria and renal insufficiency, but only 12% of nonobese patients developed these 
disorders (Praga et al., 2000).  The mechanisms underlying obesity-induced renal injury 
are unclear, but increased caloric intake (Stern et al., 2001), hypercholesterolemia 
(Maddox et al., 2002), hyperglycemia, insulin resistance and high blood pressure have 
been implicated as factors (Kincaid-Smith, 2004).  Extensive renal injury may be able to 
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promote hypertension by interfering with the sodium-handling ability of the kidney.  The 
ability of the kidney to excrete sodium is directly proportion to the functional renal tissue 
mass; when functional mass of the kidney is reduced to 10% of normal, excretion of 
sodium at any given arterial pressure will be only 10% of normal (Faber, 1996).    
 
Statement of Problem 
It is clear that excess weight is a major contributory factor to the development of 
hypertension in most patients.  In fact, this well documented relationship between obesity 
and hypertension has become the foundation for an entire field of research alternately 
known as obesity-hypertension, obesity-induced hypertension, or obesity-associated 
hypertension.  In this field, rapid advances are being made in our understanding of how 
obesity and hypertension are linked.  Moreover, a plethora of related risk factors, 
mediators, and pathways have now been identified and described.  Nonetheless, the 
relationships between these factors and the extents to which they promote obesity-
hypertension are often poorly understood.  Unscrambling the various cardiovascular and 
metabolic determinants of obesity-hypertension remains a persistent problem because 
both obesity and hypertension typically exhibit polygenic etiologies and diet-dependent 
dynamics in humans.  The judicious use of appropriate animal models promises to be an 
important tool in this quest. Robust animal models that represent various “clustered” 
metabolic disturbances (e.g. insulin resistance) allow investigators to advance the frontier 
of knowledge regarding the underlying pathophysiological relationships between obesity 
and hypertension.  In addition, animal models are vital tools for designing and evaluating 
approaches to the treatment of obesity-hypertension.   
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The purpose of the research described in this dissertation was to assess the obese Zucker 
rat as a model for obesity-hypertension.  One specific aim of the research project was to 
determine whether obese rats were more sensitive to experimental conditions known to 
induce hypertension than age- and gender-matched lean controls.  This was achieved by 
subjecting lean and obese rats to two experimental protocols that are known to induce 
hypertension in other rodent strains:  (1) the administration of DOCA-salt to 
uninephrectomized rats or (2) feeding rats a moderately high fat, high salt diet.  A second 
specific aim of this project was to test possible mechanisms through which a high fat diet 
might induce hypertension in obese rats.  Primarily, renal NO pathways were investigated 
to determine if dysfunction in the renal NO system may predispose obese rats to salt-
sensitive hypertension.  Additionally, leptin and insulin were assessed in an effort to 
understand their potential prohypertensive roles in obese Zucker rats given a high fat diet. 
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Abstract 
 
 
Objective: The objective of this study was to test the hypothesis that obesity increases 
the sensitivity of rats to experimentally induced hypertension. 
 
Design and Methods: To induce hypertension, unilaterally nephrectomized lean and 
obese Zucker rats were injected with 25 mg/kg of deoxycorticosterone acetate (DOCA) 
twice weekly for 5 weeks and given 1% NaCl to drink. Unilaterally nephrectomized 
control rats were injected with vehicle and drank tap water. Systolic blood pressure (SBP) 
was measured by the tail cuff method. Renal histology and urinary albumin excretion 
were used to assess the effects of the experimental treatment on the kidney. 
 
Results: Obese rats exhibited a significant rise in SBP four days after the start of DOCA-
salt treatment. In contrast, SBP of DOCA-treated lean rats was not significantly elevated 
from pretreatment measurements until day 22. Moreover, SBP was significantly higher 
during the plateau phase of blood pressure development in obese DOCA-salt treated rats 
(196 mm Hg) than in correspondingly treated lean rats (150 mm Hg). Both obesity and 
DOCA-salt treatment promoted glomerulosclerosis and mild tubulointerstitial damage in 
the kidney with DOCA-salt treatment exacerbating the effect of obesity. Urinary albumin 
excretion was significantly greater in obese control rats compared to lean controls and in 
DOCA-treated obese rats relative to vehicle-treated obese rats. 
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Conclusion:  Results of this study indicate that Obese Zucker rats are more sensitive to 
mineralocorticoid-induced hypertension than lean rats. This study provides experimental 
evidence supporting the epidemiological findings that obesity is a risk factor for the 
development of hypertension. 
 
Key words: deoxycorticosterone acetate, hypertension, kidney, Obese Zucker Rat, 
obesity-associated hypertension 
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Introduction 
 
Obesity is a significant risk factor for diseases such as hypertension, type II diabetes, 
coronary heart disease and a number of other conditions that adversely affect one’s health 
(Pi-Sunyer, 1993). Consequently, it is becoming an increasingly important health issue in 
developed countries where the incidence of this condition has risen dramatically over the 
past few decades (Kuczmarski et al., 1994; Mokdad et al., 1999; WHO, 2000). 
 
The link between body weight and blood pressure is well known and has been clearly 
documented in numerous epidemiological studies (Chiang et al., 1969). Evidence from 
these studies indicates that overweight and obese individuals have a higher risk of 
developing hypertension than lean individuals of the same age and gender, with the 
prevalence of hypertension increasing in proportion to the degree of overweight (Kannel 
et al., 1967).  
 
To fully elucidate the mechanism(s) through which obesity can predispose an individual 
to the development of hypertension, suitable animal models are required. One animal 
model that has received considerable attention in this arena is the obese Zucker rat. Blood 
pressures of lean and obese rats have been compared in multiple studies with varied 
results. Some investigators have reported that there is no difference between blood 
pressures of lean and obese rats (Auguet et al., 1989; Bunag and Barringer, 1988; Lavaud 
et al., 1996; Levin et al., 1984; O'Donnell et al., 1985; Pamidimukkala and Jandhyala, 
1996; Pawloski et al., 1992; Todd and Abernethy, 1986) whereas others have concluded 
that blood pressure in the obese rat is elevated relative to its age- and sex-matched lean 
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counterpart (Alonso-Galicia et al., 1996; Carlson et al., 2000; Kasiske et al., 1985; Kurtz 
et al., 1989; Paradise et al., 1985; Wickler et al., 1982; Zemel et al., 1990). The fact that 
elevated blood pressures can be recorded for the obese Zucker rat in some laboratories 
but not in others when measurements were made under comparable conditions may 
indicate that these animals have labile blood pressure regulatory mechanisms that are 
sensitive to subtle differences in environment and/or experimental protocol. In fact, 
alterations in cardiovascular regulatory mechanisms of the obese rat that could ultimately 
contribute to a rise in blood pressure were described in two of the above studies reporting 
undetectable differences in blood pressure between lean and obese rats (Bunag and 
Barringer, 1988; Pamidimukkala and Jandhyala, 1996).  Lability with respect to blood 
pressure control could make the obese rat more susceptible to the development of 
hypertension if this animal is exposed to an appropriate environmental stimulus. 
 
The objective of the present study was to demonstrate experimentally that obesity is a 
risk factor for the development of hypertension by subjecting lean and obese Zucker rats 
to a stimulus known to induce hypertension and assessing the responsiveness of the two 
groups. Data from experiments using mineralocorticoid-induced hypertension indicate 
that (1) the obese Zucker rat develops hypertension more rapidly than its lean counterpart 
and (2) the magnitude of the hypertensive response is much greater in obese rats than in 
lean rats. 
 
 
Methods 
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Animals. Female obese (fa/fa) and lean (Fa/?) Zucker rats were purchased from Charles 
River Laboratories (Wilmington, MA) at 8 weeks of age and housed in the Marshall 
University Animal Resources Facility in plastic cages with wood chip bedding in rooms 
having an ambient temperature of 23 + 2o C and a 12-hour light/dark cycle. All 
procedures using rats were approved by the Marshall University Institutional Animal 
Care and Use Committee. 
 
Deoxycorticosterone acetate (DOCA)-salt hypertension.  Nine-week-old lean and obese 
rats were unilaterally nephrectomized under ketamine HCl-xylazine (45:5 mg/kg)-
induced anesthesia. During this procedure, Marshall University Animal Resources 
Facility guidelines were strictly adhered to for aseptic surgery on rodents. Following a 
recovery period of two weeks, control blood pressure measurements were obtained twice 
weekly over an interval of two weeks. Then DOCA (25 mg/kg), suspended in corn oil, 
was administered twice weekly via subcutaneous injections to one group of lean and one 
group of obese rats for a period of five weeks. During the treatment period, 1% NaCl was 
added to the drinking water of the DOCA-treated rats. Unilaterally nephrectomized 
control lean and obese rats were injected with vehicle (corn oil) only and were given tap 
water to drink. All rats had free access to Purina rat chow. 
 
Systolic blood pressure was measured on conscious rats using a programmed 
electrosphygmomanometer with a pneumatic pulse transducer and tail cuff (Narco-
Biosystems, Houston, TX). Practice blood pressure measurements were obtained during 
the week prior to the measurement of control blood pressures so that the rats could 
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become familiar with the technique. To alleviate any stress associated with the 
environment and/or protocol, the environmental conditions in the recording room and the 
techniques for handling the rats and measuring blood pressure were carefully controlled.  
 
Measurement of urine albumin. After five weeks of DOCA treatment, control and 
DOCA-treated rats were placed in individual metabolic cages for a 24-hour urine 
collection. The 24-hour sample was obtained after the rats were allowed to adapt to the 
metabolic cage for a 24-hour period. Urine proteins were separated by one-dimensional 
sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis using a 5% stacking 
gel and a 10% separating gel. Prior to electrophoresis, urine samples were diluted with 
saline so that the density of the resultant band would fall within the linear portion of a 
curve prepared by using albumin standards.  A 5 microliter aliquot of each diluted sample 
was mixed with 20 microliters of sample buffer containing 62.5 mM Tris-HCl (pH 6.8), 
2% SDS, 10% glycerol, 5% 2-mercaptoethanol and 0.0025% bromophenol blue and 
heated at 95 oC for 5 minutes. Ten microliter aliquots of the mixture were then loaded 
onto the gel. Two lanes on each gel were loaded with 10 microliters of an albumin 
standard (2 mg/ml). Gels were run at 60 mA until the bromophenol blue dye front 
reached the bottom of the gel (approximately 1 hour) using a Bio-Rad Mini-Protean II 
Electrophoresis Cell. After electrophoresis the protein bands were stained with silver 
stain using a Silver Stain Plus kit (Bio-Rad, Richmond CA) according to the 
manufacturer’s instructions. Gels were placed in cellophane membranes and dried 
overnight in a drying frame. Subsequently, protein bands were quantified using a 
Molecular Dynamics Personal Densitometer. To normalize data from multiple gels, the 
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density of a given lane was expressed as a function of the albumin standard for that gel. 
Results are expressed in arbitrary densitometric units times the dilution factor of the 
sample.   
 
Histology. At the end of an experiment, the rats were deeply anesthetized with a ketamine 
HCl-xylazine mixture (45:5 mg/kg) and euthanized by exsanguination via cardiac 
puncture. Kidneys were removed by dissection and fixed overnight in 10% buffered 
formalin.  Following fixation, coronal sections of the kidneys were subjected to standard 
processing and embedded in paraffin. The sections were cut at 2 microns and stained with 
hematoxylin and eosin (HandE).  Additional sections were cut at 4 microns and stained 
with periodic acid-Schiff (PAS).  The slides were reviewed without knowledge of the 
experimental groups. The methods of Dworkin, Feiner and Randazzo (Dworkin et al., 
1987) were followed for the quantitative assessment of the glomeruli and a mesangial 
expansion score was obtained for each rat.  Twenty-five glomeruli were examined in each 
section and the amount of mesangial expansion was graded according to the following 
scheme: “1” if of normal area, “2” if mildly increased in area, “3” if moderately increased 
in area and “4” if markedly increased in area.  Tubular involvement was assessed semi-
quantitatively with a determination of cast formation and the amount of tubular atrophy 
and dilatation.  Both the resulting cast score and the tubular index were determined by 
counting the percent of tubules with casts or tubular dilatation and /or atrophy per 25 high 
power fields in each subject.  Both determinations were scored using the following 
schema: “1” if 0-25% of tubules were involved, “2” if >25-50% of tubules were involved, 
“3” if >50-75% of tubules were involved, and “4” if >75-100% of tubules were involved.   
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Statistics. Data are expressed as means ± SEM. Statistical analysis was performed using 
Sigma Stat statistical software (Jandel Corporation, San Rafael, CA). Differences among 
the means of different groups were assessed by two way analysis of variance followed by 
a Tukey test. A Dunnett’s test was used following two way analysis of variance of blood 
pressure data in order to compare blood pressure changes in a given group with 
pretreatment measurements. P values of 0.05 or less were interpreted as being statistically 
significant. 
 
Results 
 
At the start of the study, systolic blood pressures (SBP) for vehicle-treated unilaterally 
nephrectomized lean and obese rats were essentially the same (122 ± 3 and 127 ± 2 
mmHg, respectively). DOCA-salt-treated obese rats exhibited a significant rise in SBP 
compared to their pretreatment values as early as 4 days after the start of DOCA-salt 
treatment (Figure 2.1A). When these blood pressure measurements were compared to the 
obese control group, differences in SBP reached significance at day eight. In contrast, 
systolic blood pressure of DOCA-salt-treated lean rats was not significantly elevated 
from pretreatment measurements until day 22 (Figure 2.1B). Moreover, the magnitude of 
blood pressure elevation during the plateau phase of blood pressure development, was 
significantly greater in the obese group (196 mmHg) compared to the lean group (150 
mmHg). Because DOCA was administered on the basis of body weight (25 mg/kg) 
during the first experiment, obese rats received more DOCA than their lean counterparts. 
To control for this, obese rats were given only as much DOCA as the lean rats in a 
 39
subsequent experiment. This relative reduction in the administered amount of DOCA did 
not affect the time of onset or magnitude of the blood pressure response in the obese 
animals (Figure 2.2). 
 
At the onset of DOCA-salt treatment, obese rats weighed twice as much as age- and 
gender-matched lean rats (427 ± 5 g versus 217 ± 2 g respectively). During the 5-week 
treatment period, vehicle treated lean rats gained an average of 21.5 ± 3.1 g whereas the 
vehicle-treated obese group gained an average of 53.3 ± 6.1 g. The gain in body weights 
appeared to be unaffected by DOCA-treatment in lean rats (Figure 2.3). In contrast, 
DOCA-treatment did affect weight gain in the obese group: after an initial gain of 12 
grams during the first week of treatment, there was no further gain in weight for the 
remainder of the study (Figure 2.3). By week 5, approximately half of the rats in the 
DOCA-treated obese group were losing weight. This resulted in a mean weight for the 
group that was about 24 grams lower than the peak weight attained at week one. 
 
Sections of the kidney were examined from both control and DOCA-treated lean and 
obese rats. Dramatic morphologic changes were noted in the glomeruli of vehicle-treated 
uninephrectomized obese rats (Figure 2.4b) compared to vehicle-treated lean rats (Figure 
2.4a). These changes became more pronounced when obese rats were treated with DOCA 
(Fig.4e). While focal glomerulosclerosis was present in vehicle-treated obese rats, upon 
DOCA treatment, many glomeruli developed global glomerulosclerosis with almost 
complete replacement with eosinophillic, hyalinized material that was PAS positive. 
Moreover, glomerular changes in obese DOCA-treated rats were characterized by 
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prominent expansion of the mesangial matrix and increased mesangial cellularity. To 
assess the glomerular involvement, a semi-quantitative mesangial matrix expansion score 
was determined. In vehicle-treated uninephrectomized animals, there was a significant 
increase in the mesangial matrix score of kidneys from obese rats compared to lean rats 
(Table 2.1). In addition, DOCA-salt treatment also increased matrix scores in both lean 
and obese animals. Although the amount of matrix expansion in kidneys from DOCA-
treated obese rats was quite dramatic relative to kidneys from DOCA-treated lean rats, 
analysis of the matrix scores did not reach statistical significance due to the variability 
both within an individual kidney and between animals.  
 
In addition to the observed glomerular changes, tubular changes were also prominent in 
the DOCA-treated obese rats. These changes were characterized by a thickening of the 
tubular basement membranes, markedly dilated tubules with PAS-positive casts, and 
tubular atrophy with flattening of the tubular epithelial cells.  Although some mild cast 
formation and tubular atrophy was noted in the kidneys of vehicle-treated obese rats, 
prominent tubular cast formation along with tubular dilatation and atrophy were present 
upon DOCA administration (Figure 2.4f).  In contrast, while the lean DOCA-treated 
subjects showed some tubular changes, they were much less pronounced than that seen in 
the obese animals (Figure 2.4d). Separate scores were obtained for cast formation and for 
the development of tubular atrophy and dilatation. Differences between lean and obese 
controls and lean controls and DOCA-treated lean rats for both parameters were minor 
and statistically insignificant. In contrast, both the tubular index and the cast score for 
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kidneys from DOCA-treated obese rats were elevated significantly relative to vehicle-
treated obese rats and DOCA-treated lean rats (Figure 2.5). 
 
As a functional correlate to the histological evaluations, urine albumin content was 
measured for rats in all four experimental groups. Figure 2.6 is representative of the gels 
that were used to assess urine albumin concentration. Results of all the gels that were run 
are summarized in Figure 2.7A. This figure shows that the concentration of albumin in 
the urine of obese rats is greater than that of lean rats both in the presence and absence of 
DOCA-salt treatment. In addition, when total albumin excretion was determined using 
24-hour urine volumes (Figure 2.7B), additional findings were highlighted: (1) DOCA-
salt treatment significantly increased total albumin excretion in both lean and obese rats 
relative to their vehicle-treated counterparts and (2) albuminuria resulting from DOCA-
salt treatment was significantly greater in obese rats than in the lean rats. Urine albumin 
content of the different treatment groups was consistent with their respective mesangial 
matrix scores (Table 2.1). 
 
Discussion 
 
It has been suggested that the obese Zucker rat may be a good model for the study of 
obesity-associated hypertension (Kurtz et al., 1989). This idea is supported by data from a 
number of laboratories that indicate the blood pressure of obese Zucker rats is elevated 
relative to lean rats (Alonso-Galicia et al., 1996; Carlson et al., 2000; Kasiske et al., 
1985; Kurtz et al., 1989; Paradise et al., 1985; Wickler et al., 1982; Zemel et al., 1990). In 
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some of these studies, differences in blood pressure, although statistically significant, 
tended to be modest with little evidence of overt hypertension in animals expressing the 
obese phenotype. In other studies, obese rats exhibited borderline hypertension with 
systolic blood pressures in the range of 145-155 mmHg. This was especially the case 
when measurements were made in older animals (Kasiske et al., 1985; Paradise et al., 
1985).  In contrast, other investigators, using similar experimental conditions, have been 
unable to detect differences in the resting blood pressure of lean and obese Zucker rats 
(Auguet et al., 1989; Bunag and Barringer, 1988; Lavaud et al., 1996; Levin et al., 1984; 
O'Donnell et al., 1985; Pamidimukkala and Jandhyala, 1996; Pawloski et al., 1992; Todd 
and Abernethy, 1986). A review of these studies did not reveal any obvious factors such 
as the age or gender of the animals, the vendor supplying the rats or the methodology 
used to assess blood pressure that could readily explain why blood pressures were 
elevated in obese rats in some studies but not in others. Differences from study to study 
could have occurred because blood pressure regulation in the obese rat is more labile and, 
consequently, more sensitive to subtle differences in the physiological state of the animal 
or the environmental conditions under which it is maintained. The suggestion that obese 
animals may be more sensitive to physiological or environmental conditions that elevate 
blood pressure is consistent with the idea of obesity being a risk factor for the 
development of hypertension. 
 
In the present study, we investigated obesity as a risk factor for hypertension by 
challenging lean and obese Zucker rats with a set of experimental conditions known to 
induce hypertension (DOCA-salt administration to unilaterally nephrectomized rats) in 
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rats and then comparing the responses of animals expressing the two different 
phenotypes. The onset of hypertension in the obese rat was sudden and dramatic 
compared to the response of the lean rat. Moreover, the severity of the hypertensive 
response was much greater in obese rats than in lean rats as evidenced by the fact that 
when the blood pressures reached a plateau during the fourth and fifth weeks of the study, 
the mean blood pressure in the DOCA-treated obese group exceeded that of the DOCA-
treated lean group by more than 45 mmHg. These data strongly support the conclusion 
that obese rats are more sensitive to DOCA-salt treatment than their lean counterparts. 
The extreme sensitivity of obese rats to DOCA-salt treatment was further evidenced by 
the fact that many of the obese rats exhibited some of the more harmful effects of DOCA-
salt hypertension early in the treatment period. When Gavras and associates (Gavras et 
al., 1975) extended DOCA-salt treatment beyond the usual 4 to 5 weeks, they observed 
that the rats tended to lose weight and become moribund 6 to 10 weeks after the onset of 
DOCA administration. Similarly, Kretzler et al. (1994), Wada et al. (1995) and 
Matsumura et al. (2000) reported deaths and evidence of stroke and neurological damage 
in DOCA-salt-treated rats that were severely hypertensive. In the current study, three of 
the DOCA-salt-treated obese rats experienced seizures and about half lost weight and 
became moribund before the experiment was terminated at five weeks. In contrast, only 
one of the DOCA-salt-treated lean rats died before the end of the experiment and none 
developed seizures. 
 
An important issue with regard to rats subjected to DOCA-salt hypertension in general 
and the aging obese Zucker rat in particular is the structural and functional integrity of 
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the kidney. As the obese Zucker rat ages, it exhibits progressive renal damage. Although 
renal function is similar in lean and obese rats at 12 to 14 weeks of age, the obese rat is 
already exhibiting a small degree of proteinuria and histological evidence of mesangial 
matrix expansion at this time (Kasiske et al., 1985). By 17 weeks of age, approximately 
3% of tubules from the kidney of the obese rat exhibit evidence of mild injury and 1% to 
3% of the glomeruli exhibit early focal glomerulosclerosis (Magil, 1995). By 28 weeks of 
age, 5% of the glomeruli in the kidney of the obese rat exhibit focal glomerulosclerosis 
and there is a marked increase in urine albumin excretion. Moreover, in this age group, 
rats that have been unilaterally nephrectomized for a period of 24 weeks exhibit twice the 
incidence of focal glomerulosclerosis as two-kidney obese rats (Kasiske et al., 1989). As 
rats continue to age, there is an increased incidence of focal glomerulosclerosis and 
tubular damage. Kasiske et al. (1985) have reported that almost 32% of glomeruli from 
kidneys of 68-week-old obese rats exhibit focal glomerulosclerosis compared to just 5% 
of glomeruli from kidneys of age-matched lean rats. In addition, kidney sections from 51 
and 61-week-old obese rats have areas with markedly dilated tubules, some of which 
contain PAS-positive casts (Shimamura, 1983). Casts are rare in the tubules of younger 
obese Zucker rats (Magil, 1995). 
 
In the present study, rats were 9 weeks of age at the start of an experiment and 18-weeks-
old at its conclusion. At 18 weeks of age, one would predict a small degree of glomerular 
and tubular damage in the kidneys of vehicle-treated obese rats and significant 
albuminuria relative to that recorded for vehicle-treated lean rats. This is consistent with 
our observations. 
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Changes in renal structure induced by chronic DOCA-salt treatment in some strains of rat 
are qualitatively similar to those observed in the kidney of the aging obese Zucker rat. 
For example, in studies using Sprague-Dawley and Munich-Wistar rats, the kidneys from 
DOCA-salt treated animals exhibited mesangial matrix expansion and glomerulosclerosis 
(Dworkin et al., 1987; Kretzler et al., 1994; Shimamura, 1990). Moreover, mild tubular 
damage characterized by atrophy of the tubular epithelium, tubular dilatation and the 
presence of hyaline casts has been observed in response to DOCA-salt treatment (Kim et 
al., 1994; Matsumura et al., 2000). In the present study, the renal effects of DOCA-salt 
treatment in the lean Zucker rat were comparable to those reported for other stains of rat: 
a modest increase in the mesangial matrix and mild tubular dilatation. In contrast, the 
effects of DOCA-salt treatment on the kidney of the obese Zucker rat were far more 
severe. In many glomeruli, global glomerulosclerosis was evident with the glomerulus 
being replaced by hyaline material. DOCA-salt effects on renal tubules were even more 
remarkable: many tubules in the obese rat kidney were markedly dilated, had a flattened 
epithelial lining and were filled with casts. Moreover, the striking structural changes in 
the kidney of the DOCA-salt treated obese rat were paralleled by an equally dramatic 
increase in the level of albuminuria. These observations suggest that DOCA-salt 
treatment may be accelerating the progressive renal injury that occurs in the aging obese 
Zucker rat.  
 
One problem associated with research involving genetic models of obesity is that it is 
often difficult to determine whether the observed effect is due to obesity per se or to the 
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expression of the mutated gene. In the obese Zucker rat, obesity is due to a mutated leptin 
receptor (Chua et al., 1996; Takaya et al., 1996). Leptin is a peptide produced by adipose 
tissue that plays an important role in the long-term regulation of food intake and energy 
expenditure.  It has been suggested that leptin may also play a role in blood pressure 
regulation and possibly in the development of hypertension. When administered to 
normotensive rats, leptin causes a modest increase in blood pressure (Carlyle et al., 2002; 
Dunbar et al., 1997; Fruhbeck, 1999; Shek et al., 1998), an effect that may be due to a 
leptin-induced increase in sympathetic activity (Dunbar et al., 1997; Hall et al., 2001). 
The obese Zucker rat, which has an abnormal leptin receptor, appears to be resistant to 
the effect of leptin on sympathetic activation (Haynes, 2000) and blood pressure 
elevation (Fruhbeck, 1999). It is this resistance to the effects of leptin that could make the 
obese Zucker rat more susceptible to DOCA-salt hypertension. When lean Zucker rats are 
given an IV bolus injection of leptin, there is a marked increase in urine sodium excretion 
(Villarreal et al., 1998). This natriuretic effect of leptin is greatly attenuated in the obese 
Zucker rat (Villarreal et al., 1998). If leptin is shown to play a significant regulatory role 
in allowing an animal to adjust to an increased sodium load, then resistance to this effect 
could make the obese rat more susceptible to the development of DOCA-salt 
hypertension. Further studies are needed to test this hypothesis and to determine whether 
the increased susceptibility of the obese Zucker rat to DOCA-salt hypertension is due to 
obesity per se or the consequence of a mutated leptin receptor. 
 
In conclusion, results of this study indicate that young obese Zucker rats, with resting 
systolic blood pressures that are indistinguishable from age- and sex-matched lean rats, 
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may be more sensitive to conditions that promote the development of hypertension than 
their lean counterparts. Furthermore, these results support the conclusion of others that 
the obese Zucker rat may be a useful model for the study of obesity-associated 
hypertension.  
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Figures and Tables 
 
 
 
Table 2.1. Mesangial matrix scores of vehicle 
and DOCA-salt treated lean and obese Zucker 
rats.  
 
Group   Mesangial Matrix Score 
 
Lean 1-kidney Control 1.36±0.17 
Lean 1-kidney DOCA  2.26±0.16 
 
Obese 1-kidney Control 2.40±0.17 
Obese 1-kidney DOCA 2.98±0.15 
 
Data are expressed as the mean ± SEM for each 
group. The mesangial matrix score is 
significantly affected (p<0.05) by both the 
phenotype and DOCA-salt treatment. 
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Figure 2.1.  Systolic blood pressure (SBP) in obese (A) and lean (B) rats before and during DOCA-
salt treatment. The arrow indicates the time when DOCA-salt treatment was initiated (Day 0). 
Nineteen obese rats and 13 lean rats were injected twice-weekly with DOCA (25mg/kg) in corn oil 
and given 1% NaCl in their drinking water. Sixteen obese rats and 13 lean rats were injected with 
vehicle (corn oil) and given tap water to drink. * P<0.05 compared to pretreatment SBP for that 
group.   
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Figure 2.2.  Effects of reducing the amount of DOCA administered to obese Zucker rats on SBP. In 
this experiment, age-matched lean and obese rats were given the same absolute amount of DOCA. 
The quantity of DOCA administered to the obese rats (N=7) was based upon the weight of the age-
matched lean rats. The magnitude of the blood pressure response and time required to cause a 
significant elevation in blood pressure were essentially the same as for obese rats given DOCA at a 
dose of 25 mg/kg. *P<0.05 compared to both pretreatment blood pressures for the reduced-DOCA 
obese group and blood pressures for age-matched vehicle-treated obese rats. 
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Figure 2.3. Changes in body weights of lean and obese rats in response to DOCA-salt treatment. Rats 
were injected twice weekly with DOCA (25 mg/kg) in corn oil and given 1% NaCl in their drinking 
water. Vehicle-treated rats were injected twice weekly with corn oil only and given tap water to 
drink. *P<0.05 compared to vehicle treated rats at the same time interval. 
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Figure 2.4. Light micrographs of hematoxylin and eosin prepared kidney sections at 600X 
magnification. (a) Lean control kidney showing essentially normal glomeruli and tubules. (b) Obese 
control kidney showing a mild increase in the mesangial matrix and some tubular dilatation. (c) Lean 
DOCA-treated kidney showing a glomerulus with a moderate increase in the mesangial matrix and 
some surrounding mild tubular dilatation. (d) Lean DOCA-treated kidney showing mild tubular 
dilatation. (e) Obese DOCA-treated with severe global glomerulosclerosis with the glomerulus 
replaced by amorphous hyaline material. (f) Obese DOCA-treated kidney showing very dilated 
tubules filled with casts and showing atrophy with flattening of the tubular lining epithelium. 
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Figure 2.5. Tubular indices (A) and cast scores (B) for kidneys from DOCA- and vehicle-treated lean  
(Ln) and obese (Ob) Zucker rats. Each bar represents the mean and each bracket the SEM of scores 
from 5 to 7 different kidneys in each group. *P<0.05 compared to the vehicle-treated obese group; 
+P<0.05 compared to the DOCA-treated lean group. 
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Figure 2.6. SDS-PAGE gel showing urine albumin content. Urine samples were subjected to SDS-
PAGE and the gels were stained with silver stain as described in the methods section. Lanes 1 and 8 
contained an albumin standard (2 mg/ml), lanes 2 and 4 contained urine from DOCA-treated lean 
rats, lane 3 urine from a vehicle-treated lean rat, lanes 5 and 7 urine from DOCA-treated obese rats 
and lane 6 urine from a vehicle-treated obese rat.  
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Figure 2.7. Albumin excretion in DOCA- and vehicle-treated lean (Ln) and obese (Ob) Zucker rats. 
Aliquots of 24-hour urine samples were diluted and subjected to SDS-electrophoresis and 
densitometric analysis. Urine albumin concentration, expressed as relative density in panel A, was 
determined by comparing the density of the albumin fraction of each urine sample with that of a 
known concentration of albumin standard run on the same gel. In panel B, the total amount of 
albumin excreted in a 24-hour period was obtained by multiplying the relative density of the albumin 
band times the 24-hour urine volume. Each bar represents the mean and each bracket the SEM of 
urine samples from 6 different rats. *P<0.05 compared to urine samples of lean rats subjected to the 
same treatment; +P<0.05 compared to the vehicle-treated group of the same phenotype. 
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Abstract 
 
The objective of this study was to assess the progression of renal damage in obese Zucker 
rats in response to deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Renal 
damage was evaluated by light microscopy and urine analysis at weekly intervals during 
the developmental phase of DOCA-salt hypertension and once during the plateau phase 
42 days after the onset of treatment.  Decreased tubular function was evident by day 8, as 
indicated by a significant increase in urine N-acetyl-β-D-glucosaminidase activity and 
glucose excretion.  The tubular index, a measure of tubular damage, was significantly 
elevated by day 15 and continued to increase throughout the experiment.  Glomerular 
damage, which was evident by day 8, was followed by increased urine albumin excretion 
by day 15. Only a few sclerotic glomeruli were apparent before the plateau phase; 
however, by day 42, approximately 50% of the glomeruli were sclerotic.  Hyperplastic 
vascular changes were mild at day 8 and slowly increased in severity during the 
developmental phase. By day 42 the vascular changes were quite dramatic with some 
vessels being so hyperplastic that their lumens were almost occluded. Overall, these 
findings show progressive changes in renal structure and function that begin as early as 
day 8 and increase over time until dramatic changes are present at day 42, resulting in an 
end stage kidney. 
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Introduction 
 
Data from multiple national surveys clearly demonstrate a dramatic rise in the incidence 
of obesity (a body mass index in excess of 30) in the United States over the past 25 years 
(Flegal et al., 1998; Flegal et al., 2002; Mokdad et al., 1999). Because obesity is a risk 
factor for multiple disorders such as type 2 diabetes, coronary heart disease, and 
hypertension (Pi-Sunyer, 2002), the progressive increase in the incidence of obesity has 
become a serious health concern.  
 
Obesity is a well-established risk factor for hypertension with the incidence of 
hypertension for obese adults being almost three times that observed for non-obese 
individuals (Van Itallie, 1985). The consequences of chronic hypertension include serious 
end organ damage resulting in cardiac and vascular hypertrophy, stroke and/or renal 
damage. In the kidney, hypertension may initiate renal damage or it may promote the 
progression of previously established renal disease (Klahr et al., 1988). Hypertension-
associated renal damage has been demonstrated in both clinical (Brazy et al., 1989; Klag 
et al., 1996) and experimental studies (Dworkin et al., 1984). 
 
While much attention has been focused on the role of hypertension in progressive renal 
damage, less is known about the effects of obesity per se on renal structure and function. 
A recent retrospective study suggests that obesity by itself may promote the development 
of focal glomerulosclerosis and glomerulomegaly (Kambham et al., 2001). The 
glomerular changes observed in renal biopsies from this study were similar to those 
observed by Kasiske et al. (1985) and Shimamura (1983) in their work with the mature 
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obese Zucker rat, a genetically obese animal that has been used as an experimental model 
to study obesity-associated glomerulosclerosis (Gassler et al., 2001; Kamanna and 
Kirschenbaum, 1993; Kasiske et al., 1991; O'Donnell et al., 1985). 
 
The obese Zucker rat may also be useful as an experimental model to assess the 
interaction between obesity and hypertension in the promotion of progressive renal 
damage. We have recently reported that obese Zucker rats exhibit an enhanced sensitivity 
to deoxycorticosterone-salt (DOCA-salt)-induced hypertension. In this study, systolic 
blood pressure rose more rapidly and the magnitude of the hypertensive response was 
significantly greater in obese rats treated with DOCA-salt than in correspondingly treated 
age- and gender-matched lean rats (Morrison et al., 2002). Moreover, marked 
glomerulosclerosis and tubulointerstitial damage were evident in kidneys of hypertensive 
obese rats at the end of the study whereas DOCA-salt treated lean rats exhibited only 
modest changes in renal histology.  
 
The objective of the present study was to use biochemical and morphologic measures to 
assess the temporal pattern of change in the kidney of obese Zucker rats in response to a 
course of DOCA-salt administration. Biochemical abnormalities reflective of both tubular 
and glomerular damage were seen early and progressively during the developmental 
phase of the hypertensive response. Likewise, changes in tubular, glomerular and 
vascular morphology occurred early and continued to increase in extent and severity over 
the course of the study. The glomerular damage involved the development of mesangial 
hypercellularity with an endpoint of glomerulosclerosis. Progressive changes in the 
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tubules included tubular dilatation, atrophy of tubular epithelial cells and cast formation.  
The vascular changes were quite prominent with the development of hyperplastic 
arteriolosclerosis that increased dramatically in severity over time, culminating in the 
appearance of plexiform lesions and nearly complete vessel occlusion by the end of the 
study.   
 
Materials and Methods 
 
Animals.  Eight-week-old female obese (fa/fa) Zucker rats were purchased from Charles 
River Laboratories (Wilmington, Massachusetts, USA) and housed in the Marshall 
University Animal Resources Facility in plastic cages with wood chip bedding in rooms 
having an ambient temperature of 23±2 °C and a 12 h light/dark cycle. Rats were allowed 
to acclimate to this facility for one week prior to being incorporated into an experimental 
study. All procedures using rats were approved by the Marshall University Institutional 
Animal Care and Use Committee.  
 
Experimental procedures using animals.  Nine-week-old rats were deeply anesthetized 
with a mixture of ketamine HCl and xylazine (45:5 mg/kg) and then unilaterally 
nephrectomized under aseptic conditions as prescribed by Marshall University Animal 
Resources Facility guidelines for aseptic surgery on rodents. Following surgery, rats were 
allowed to recover for a period of two weeks before being subjected to further 
experimental manipulation. After the recovery period, the rats were familiarized with the 
blood pressure measurement protocol for an additional week before blood pressure 
measurements for the experiment were begun. Throughout the study, body weights were 
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measured twice weekly and the systolic blood pressure (SBP) measured once weekly on 
conscious rats by tail cuff plethysmography using a programmed 
electrosphymomanometer with a pneumatic pulse transducer and tail cuff (Narco-
Biosystems, Houston, Texas, USA). 
 
Deoxycorticosterone acetate (DOCA)-salt hypertension was induced by means of 
biweekly subcutaneous injections of DOCA (25 mg/kg) suspended in corn oil. During the 
DOCA-treatment period, 1% NaCl was added to the drinking water. All rats had free 
access to Purina rat chow throughout the study. Five randomly selected rats were not 
treated with DOCA. These rats were sacrificed one day after the beginning of the DOCA-
salt treatment (“Day 1”) to obtain kidneys for histological analysis.  
 
Six days prior to the start of DOCA-salt treatment and at weekly intervals during the 
developmental phase of the hypertensive response, 6 rats were placed in stainless steel 
metabolic cages to measure food and water consumption and 24-hour urine output and to 
collect urine for assessing renal function. The animals were given 1 day to adapt to the 
metabolic cages before measurements were obtained and samples collected. Urine 
samples were collected at 6- and 24-hours with the 6-hour urine sample being collected in 
a cold container. Immediately upon collection, the urine samples were centrifuged and 
the supernatant stored at -20o C until used for analysis. 
 
Analytical procedures.  The Bradford (Bradford, 1976) technique was used to measure 
the total protein content of urine with the data being expressed as mg of protein excreted 
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per 24 hours. Urine albumin levels were measured as described previously (Morrison et 
al., 2002). Briefly, aliquots of a 24-hour urine sample were diluted with 0.9% NaCl and 
separated by one-dimensional SDS-PAGE using a 5% stacking gel and a 10% separating 
gel. Following electrophoresis, the gels were stained using a Silver Stain Plus kit (Bio-
Rad, Richmond CA) according to the instructions of the manufacturer and then dried 
overnight. Protein band density was measured with a Molecular Dynamics personal 
densitometer and the intensity of each protein band was expressed as a function of the 
albumin standard run with that gel. Samples high in protein content were diluted with 
0.9% NaCl before being subjected to electrophoresis so that their densities would fall 
within the linear portion of a densitometric curve prepared with increasing concentrations 
of an albumin standard. Results are expressed as arbitrary densitometric units times the 
dilution factor of the individual 24-hour urine sample.  
 
Urinary excretion of the lysosomal enzyme, N-acetyl-β-D-glucosaminidase (NAG), and 
glucose were used as indices of renal tubular integrity. To remove inhibitors, urine 
samples were fractionated on a Sephadex G-50 gel filtration column before being assayed 
for NAG activity by means of a colorimetric assay (Roche Diagnostics, Indianapolis, IN). 
NAG content is expressed in terms of mU of NAG activity in a 24-hour urine sample. 
Urine glucose levels were measured using a Beckman Glucose Analyzer 2 (Beckman 
Instruments, Brea, CA) with the data being expressed as mg glucose excreted per 24 
hours.  
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Histological methods.  At weekly intervals, five randomly selected rats were deeply 
anesthetized with a ketamine HCL-xylazine mixture (45:5 mg/kg) and euthanized by 
exsanguination via cardiac puncture.  Kidneys were removed and sliced into sections that 
were fixed overnight in 10% buffered formalin. Each kidney was entirely sectioned, and 
two representative sections were subjected to standard processing and embedded in 
paraffin.  Sections were cut at 2 µm and stained with hematoxylin and eosin (HandE). 
Thin sections were utilized to enhance morphologic detail.  Slides were reviewed without 
knowledge of the experimental groups. Twenty-five glomeruli were examined in each 
section and the amount of mesangial expansion was graded as follows: "1" if the 
mesangial area was normal, "2" if the area was mildly increased, "3" if it was moderately 
increased, and 4 if it was markedly increased. Mesangial expansion scores were 
calculated for each rat according to the procedure described by Dworkin et al (Dworkin et 
al., 1987).  In addition, the percentage of sclerotic glomeruli was determined by assessing 
a total of 25 glomeruli in each section and counting the number of glomeruli that 
demonstrated sclerosis. Tubular involvement was assessed semi-quantitatively by 
determining a cast score and tubular index for each rat. Cast scores were obtained by 
counting the percentage of tubules with casts per 25 high power fields and the tubular 
index was determined by counting the percentage of tubules exhibiting tubular atrophy 
and/or dilatation per 25 high power fields. Both determinations were scored as follows:  
‘1’ if 0-25% of tubules were involved, ‘2’ if >25-50% of tubules were involved, ‘3’ if 
>50-75% were involved, and ‘4’ if > 75-100% of tubules were involved. 
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Statistics.  Data are expressed as means ± SEM.  Statistical analysis was performed using 
Sigma Stat statistical software (Jandel Corporation, San Rafael, California, USA). 
Following normality and equal variance testing, comparisons between groups were made 
using one-way analysis of variance and, afterward, a Dunnett's test for making multiple 
comparisons against the untreated control group. When sample sizes were unequal, a 
Dunn's test was used instead. Three data sets failed the normality test and were subjected 
to Kruskal-Wallis one-way analysis of variance on Ranks followed by a Dunn's test to 
make multiple comparisons against the untreated control group. P values of ≤0.05 were 
interpreted as being statistically significant. 
  
 
Results 
 
In obese Zucker rats subjected to DOCA-salt treatment, systolic blood pressure increases 
progressively over a period of about 4 weeks (developmental phase) then tends to plateau 
at severely hypertensive levels (Morrison et al., 2002). In the present study, changes in 
the morphology of kidneys from DOCA-salt-treated obese rats were assessed at weekly 
intervals during the developmental phase of hypertension and at one point two weeks 
after systolic blood pressure reached a plateau. During the developmental phase, temporal 
changes in renal function were also monitored.   
 
Twenty-four hour urine output was measured at weekly intervals and, as expected, 
DOCA-salt treatment caused a progressive increase in the total amount of urine excreted 
beginning soon after the initial injection of DOCA on day 0 (Figure 3.1).  At all time 
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points after day 1, there was a significant increase in urine volume compared to the 
control measurements which were collected 6 days prior to the initial administration of 
DOCA. The increases in urine volume were accompanied by corresponding increases in 
fluid consumption (Table 1).  
 
Randomly selected rats were sacrificed just prior to the start of DOCA-salt treatment and 
at weekly intervals thereafter.  The remaining kidney was removed from each animal, 
sectioned, and examined by light microscopy using HandE staining.  Thin sections from 
all time points were examined and significant changes were noted within the tubules.   
The normal architecture of the tubules was progressively altered over time and 
characterized by tubular disarray, dilatation of the tubular lumens, atrophy of the tubular 
epithelium, and loss of epithelial cell nuclei (Figure 3.2).  Hyaline casts were noted 
within the tubules in a number of animals.  Although they appeared to increase over time, 
the casts were focal in distribution and were not present in all animals. For a semi-
quantitative assessment of tubular injury, both a tubular index and a cast score were 
determined for each animal.   The tubular index for kidneys from DOCA-salt-treated 
obese rats began to rise as early as day 8 and increased progressively over time during the 
developmental phase of the hypertensive response: statistical significance was reached by 
day 15 (Figure 3.3A).  Cast scores, in contrast to the tubular index, were not statistically 
significant until day 42 (Figure 3.3B), although there was a trend toward increased values 
beginning at day 22. Changes in tubular function were also evaluated during the 
developmental phase of the hypertensive response. NAG activity, a sensitive measure of 
tubular integrity (Vanderlinde, 1981), peaked in the urine of DOCA-salt-treated rats at 
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day 8 and remained significantly elevated compared to untreated controls throughout the 
collection period (Figure 3.4B).  Another biochemical measure of tubular damage is 
glucose excretion (Figure 3.4A).  Urine glucose excretion was also significantly elevated 
by day 8 and increased progressively throughout the collection period.  
 
Glomerular changes were also assessed using both biochemical and morphologic 
measures.  Twenty-four-hour urine albumin excretion, an important measure of 
glomerular function, showed a statistically significant increase beginning at day 15 
(Figure 3.5B). In addition, total urine protein was measured and exhibited changes 
similar to those observed for urine albumin with a significant increase being seen by day 
15 (Figure 3.5A).  Light microscopic review of the kidney sections revealed increased 
glomerular cellularity, primarily in the mesangium, beginning as early as day 8 (Figure 
3.6).  This progressively increased over all time points to day 29.  No sclerotic glomeruli 
were observed in sections obtained from rats during the developmental phase of the 
hypertensive response.  To obtain a semi-quantitative measure of the increased 
cellularity, a mesangial matrix score was determined.  The mesangial matrix score was 
significantly elevated by 8 days of DOCA-salt treatment and continued to increase 
progressively throughout the developmental phase of the hypertensive response (Figure 
3.7).  Sclerotic glomeruli, which were not evident during the developmental phase, began 
to appear at the beginning of the plateau phase. Two weeks into the plateau phase, 50% 
of the glomeruli were sclerotic (Figure 3.7).  
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Sections from all time points were carefully examined for vascular changes.  Special 
attention was paid to the afferent and efferent glomerular arterioles along with the 
peritubular vessels. No vascular changes were noted in the untreated animals.  Overall, 
both the glomerular arterioles and peritubular vessels showed hyperplastic 
arteriolosclerotic changes with treatment (Figure 3.8). These changes were characterized 
by intimal thickening, caused by the proliferation of smooth muscle cells and the 
concentric layering of collagen, and a progressive narrowing of the vascular lumens.  
Initially, the vascular changes were mild and focal. They slowly increased in both 
severity and extensiveness from day 8 through day 29 (Figure 3.8).  Marked findings 
were seen at day 42 with some vessels so hyperplastic that the lumen was almost 
occluded.  Focal fibrinoid necrosis was present in the luminal areas of the vessels; 
however, the hyperplastic changes were most prominent.  The hyperplastic changes were 
so prominent that some vessels even formed plexiform type structures (Figure 3.8f).  At 
this time point, the kidneys were severely damaged in all areas and constituted an end 
stage kidney. 
  
 
Discussion 
 
In the present study, DOCA-salt hypertension was used to assess temporal changes in 
renal structure associated with the development of hypertension in genetically obese rats. 
DOCA-salt hypertension has been used by a number of laboratories as a tool to study the 
interactions between hypertension and other factors that lead to the progression of renal 
disease. Janssen and associates (Janssen et al., 2003), for example, have demonstrated 
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that the Goto Kakizaki rat, a model of non-obese type II diabetes, exhibits more 
pronounced proteinuria and tubulointerstitial damage when subjected to DOCA-salt 
treatment than age- and gender-matched rats of the parent strain. Investigators assessing 
interactions between Heymann nephritis and hypertension have also used the DOCA-salt 
model of hypertension and have shown that rats immunized with a renal brush border 
extract exhibit an increased sensitivity to the development of DOCA-salt hypertension, a 
greater degree of glomerulosclerosis and proteinuria (Tikkanen et al., 1980) and an 
enhanced production of cytokines and growth factors that are thought to promote renal 
damage (Tikkanen et al., 1995) than non-immunized rats that are treated with DOCA-
salt.  Similarly, we have shown that obesity greatly exacerbates the hypertensive response 
and the degree of end organ damage associated with the development of DOCA-salt 
hypertension (Morrison et al., 2002). Compared to lean littermates, the development of 
DOCA-salt hypertension is accelerated in the obese Zucker rat and the magnitude of the 
hypertensive response that is attained is markedly higher. Moreover, the degree of renal 
damage is significantly greater in obese rats than in lean rats. 
 
Because they are inclined to develop renal injury in the absence of any external 
manipulation, DOCA-salt-treated obese Zucker rats appear to provide a good model for 
studying the interactions between two factors that independently promote the progression 
of renal damage: obesity and hypertension. To this end, it has been clearly demonstrated 
that the spontaneous development of glomerulosclerosis (Kasiske et al., 1985; 
Shimamura, 1983) and tubulointerstitial damage (Magil, 1995) tends to occur more 
frequently in Zucker rats expressing the obese phenotype than in age- and gender-
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matched lean rats. In these animals, the development of glomerulosclerosis is preceded 
by a significant elevation in urine albumin excretion and mesangial matrix expansion 
(Kasiske et al., 1985). 
 
In the present study, obese Zucker rats subjected to DOCA-salt treatment exhibited 
histological evidence of glomerular, tubular and vascular abnormalities early during the 
developmental phase of hypertension. Mesangial hypercellularity and an enlargement of 
the entire glomerular complex characterized the initial glomerular response. This was 
reflected by a statistically significant increase in the mesangial matrix score by day 8 of 
treatment. At this point in the experiment, the rats were exhibiting only a mild degree of 
hypertension with the average systolic blood pressure for the group being 143.8 + 4.8. 
The extent and severity of glomerular changes increased steadily over time. By day 29, 
the mesangial matrix score reached its maximum and sclerotic glomeruli began to appear 
in kidney sections. Also by day 29, the steady rise in blood pressure reached a plateau 
phase characterized by systolic blood pressures in excess of 195 mmHg. It was during the 
plateau phase that the number of sclerotic glomeruli increased dramatically. The 
development of sclerosis is an end stage pathological response to injury in a glomerulus. 
The mechanism underlying the development of glomerulosclerosis in DOCA-salt 
hypertension has not been clearly defined although there is evidence that injury to the 
glomerulus caused by a variety of conditions leads to the excessive production of growth 
factors and cytokines by mesangial cells and the attraction of inflammatory cells that may 
promote this process (Becker et al., 2001).  
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Biochemical markers of the functional integrity of the glomerulus (urine albumin 
excretion), and tubules (urine NAG activity and glucose excretion) were also monitored 
during the developmental phase of the hypertensive response. Significant increases in 
urine NAG activity and glucose excretion were evident before there was a significant 
increase in urine albumin excretion, suggesting that, in the obese rat, the functional 
integrity of the tubules may be compromised more rapidly during the initial phase of 
DOCA-salt treatment than that of the glomeruli. 
 
A significant rise in urine NAG activity and glucose excretion also preceded a 
statistically significant increase in the tubular index. The tubular index, a calculation used 
to quantify changes in tubular morphology, was significantly elevated by day 15 and 
continued to rise steadily throughout the remainder of the study. In contrast, the cast 
score, which measures the presence of casts in the tubules, was elevated significantly 
only after the kidney had been chronically subjected (day 42 in the process) to the severe 
levels of hypertension associated with the plateau phase of the hypertensive response. 
This observation, coupled with the findings that cast distribution was focal and that casts 
were not present in all kidneys during the developmental phase of the hypertensive 
response, suggests that cast formation may be a consequence of end stage renal disease 
brought on by the prolonged exposure of the kidneys to severe hypertension.  
 
A unique feature of the present study is that we were able to observe the progression of 
renal damage throughout the developmental phase and well into the plateau phase of the 
hypertensive response. Comparisons of our results with other studies, however, are 
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limited to those changes associated with the plateau phase because most studies that have 
addressed changes in renal morphology in response to DOCA-salt administration are 
typically terminated only after the plateau phase has been reached. In studies that are 
terminated after 4 to 6 weeks of treatment, the effects of DOCA-salt administration on 
the glomeruli, tubules and small vessels of the kidney are qualitatively similar. The extent 
of the damage, however, varies from study to study with the degree of damage to the 
kidney and the incidence of mortality in obese Zucker rats being comparable to the more 
severe responses reported for DOCA-salt administration (Gavras et al., 1975; Kretzler et 
al., 1994; Wada et al., 1995). Variations in susceptibility to DOCA salt treatment have 
thus far been attributed, in part, to factors such as age (Kretzler et al., 1994; Wada et al., 
1995) or strain (Hartner et al., 2003). We have demonstrated that an obese phenotype also 
has a profound impact upon the response of a rat to DOCA-salt administration. As shown 
previously (Morrison et al., 2002), the degree of glomerular and tubulointerstitial damage 
in the lean Zucker rat treated with DOCA-salt appears to be relatively mild. In contrast, 
obese littermates of the same gender exhibit profound glomerulosclerosis, 
tubulointerstitial damage and vascular injury when subjected to an identical treatment 
regimen. 
 
The progressive changes in the glomeruli and tubules beginning at day 8 and slowly 
increasing at all time points during the development phase may provide a good model to 
study the chronic renal changes that occur with hypertension and obesity.   In contrast, 
the dramatic vascular changes occurring most extensively at day 42 may provide a good 
model for studying malignant hypertension.   Hyperplastic arteriolosclerosis is associated 
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with malignant hypertension which often occurs in patients with existing benign 
hypertension.  Although we did not demonstrate vascular hyaline arteriolosclerosis that 
can be seen in patients with chronic hypertension, we did demonstrate changes in the 
glomeruli and tubules, as noted above.  The dramatic vascular changes observed at day 
42, accompanied by a marked increase in both tubular and glomerular damage, suggest 
that the sustained and dramatic increase in blood pressure leads to an end stage kidney. 
 
In summary, we have used histological examination and biochemical markers to assess 
renal changes associated with the development of hypertension in obese rats. By doing 
so, we have observed that (1) there is evidence of renal injury very early in the 
development phase of the hypertensive response when the level of hypertension is mild, 
(2) the degree of renal injury increases with the rise in blood pressure during the 
developmental phase, (3) the functional integrity of tubules in the kidney of the obese rat 
may be more sensitive to injury induced by DOCA-salt hypertension than that of the 
glomeruli, and (4) certain indices of progressive renal damage such as glomerulosclerosis 
and cast formation  are only evident after the plateau phase of the hypertensive response 
has been reached. We conclude that the obese Zucker rat may be a good model to study 
interactions between obesity and hypertension on the progression of renal damage.   
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Figures and Tables 
 
Table 3.1. Body weights, food and water consumption, and systolic blood pressure before 
(day -6) and during the DOCA-salt treatment period (days 1-22). 
 
Day     -6     1     8    15    22 
 
 
Body weight  380.8  394.5  410.8  423.2  416.5 
(grams)    ±8.6    ±7.6    ±8.2    ±9.9  ±13.7 
 
Food Consumption   25.5    12.7    23.0    25.8    22.4 
(grams/24 hours)   ±1.1    ±2.1    ±1.5    ±1.6    ±0.7 
  
Water Consumption   47.7    57.8   110.8a    150.7a    171.0a 
(ml/24 hours)    ±1.0    ±6.8     ±5.2   ±12.2     ±2.9 
 
Blood Pressure 120.4  132.6   143.8a   150.5a   160.3a 
(mmHg)    ±2.2    ±3.6     ±4.8     ±5.6     ±5.7 
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ap<0.05 compared to day -6.  Data are expressed as the mean ± SEM for each group 
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Figure 3.1.  The effect of DOCA-salt treatment on urine volume. For each collection period, rats were 
placed in individual stainless steel metabolic cages for 48 hours. During the last 24 hours, urine 
output was measured. Urine samples were collected six days (day -6) prior to and 1 day after the 
initial DOCA injection (day 0) and at weekly intervals thereafter. Each point is the mean ± SEM for 
6 rats. *P<0.05 compared to urine formation on day -6. 
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Figure 3.2.  Histological changes occurring in the kidney tubules examined at the following time 
points: A-control, B-day 8, C-day 15, D-day 22, E-day 29, and F-day 42. All pictures were taken at 
600x except panel A which was taken at 400x.  The lower power was utilized for the control kidneys 
(panel A) to allow assessment of a larger field and confirm the lack of histological changes. 
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Figure 3.3.  The effect of DOCA-salt treatment on renal tubules. Tubular indices and cast scores 
were determined on HandE sections of kidneys as described in the methods. Each point represents 
the mean ± SEM of the tubular index (A) or cast scores (B) from 5 rats subjected to DOCA-salt 
treatment for the number of days indicated on the X-axis. *P<0.05 compared to the untreated 
uninephrectomized controls (Day 0). 
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Figure 3.4.  The effect of DOCA-salt treatment on the excretion of glucose and N-acetyl-
glucosaminidase (NAG). Urine glucose levels (A) and NAG activity (B) were determined in 24-hour 
urine samples collected six days (day -6) prior to the initial DOCA injection (day 0), one day after the 
first DOCA injection and at weekly intervals thereafter. Urine NAG content is expressed in terms of 
mU of NAG activity excreted in 24-hours.  Each point is the mean ± SEM for 6 rats. *P<0.05 
compared to glucose content or NAG activity in urine collected from rats on day -6.  
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Figure 3.5.  The effect of DOCA-salt treatment on protein and albumin excretion. Total protein (A) 
and albumin (B) levels were measured in 24-hour urine samples obtained six days (day -6) prior to 
the initial DOCA injection (day 0), one day after the first DOCA injection and at weekly intervals 
thereafter. Total protein is expressed as mg of protein excreted per 24 hours. Urine albumin content 
is expressed as arbitrary densitometric units per unit volume times the appropriate dilution factor 
for each 24-hour urine sample. Each point is the mean ± SEM for 6 rats. *P<0.05 compared to total 
protein or albumin content of urine collected from rats on day -6. 
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Figure 3.6.  Histological changes occurring in the glomeruli examined at the following time points: A-
control, B-day 8, C-day 15, D-day 22, E-day 29, and F-day 42. All pictures were taken at 600x, except 
panel E was taken at 400x. Note the arrow in panel a.  This is highlighting a small vessel in the 
control animal.  Panel E was taken at a lower power to allow visualization of two glomeruli, 
illustrating the mesangial proliferation present. 
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Figure 3.7.  The effect of DOCA-salt treatment on mesangial expansion and the formation of sclerotic 
glomeruli. Mesangial matrix scores were determined on HandE sections of kidneys as described in 
the methods. Each point represents the mean ± SEM of matrix scores from 5 rats subjected to 
DOCA-salt treatment for the number of days indicated on the X-axis. The vertical bars represent the 
percentage of sclerotic glomeruli at the indicated days. Sclerotic glomeruli were not evident before 
day 28.  *P<0.05 compared to the untreated uninephrectomized controls (Day 0). 
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Figure 3.8.  Histological changes occurring in the vessels examined at the following time points: A-
day 8, B-day 15, C-day 22, D-day29, E-day 42, and F-day 42. All pictures were taken at 600x. Part F 
demonstrates the plexiform structures present. 
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Abstract 
Objective(s):  The objective of the present study was to evaluate the obese Zucker rat as 
model of obesity-hypertension.  A high fat, salt supplemented diet was used to determine 
whether the obese Zucker rat was more susceptible to the development of hypertension. 
 
Design:  Eight-week-old female lean and obese Zucker rats were fed a diet high in fat 
content or standard rat chow (control diet) for 10 weeks. From the 4th week until the 10th 
week, 1% NaCl was added to their drinking water.  Animals were sacrificed at the end of 
the 10th week for analysis of blood leptin and insulin levels.  
 
Methods:  Blood pressure was measured at weekly intervals.  Urinary excretion of nitric 
oxide (NO) metabolites was determined by colorimetric assay at week 4 and 10.  At the 
end of the experiment, plasma insulin and leptin concentrations were determined by 
radioimmunoassay and renal nitric oxide synthase (NOS) activity was assessed in kidney 
homogenates.   
 
Results:   The blood pressure of obese, but not lean, Zucker rats on a high fat diet was  
increased by 2 weeks after onset of salt supplementation. The excretion of NO 
metabolites, a measure of systemic NO production, was inhibited by the high fat diet, 
especially in obese rats.  The high fat diet suppressed renal NOS activity in obese Zucker 
rats on the high fat diet.  The high fat diet increased plasma leptin in lean, but not obese, 
Zucker rats.  Conversely, the diet increased plasma insulin in obese, but not lean zucker 
rats. 
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Conclusions:  Data from these experiments indicate that obese Zucker rats are more 
sensitive than age- and gender-matched lean counterparts to the development of diet-
induced hypertension in response to a moderately high fat, salt-supplemented diet.  
Furthermore, this obesity-associated susceptibility to hypertension is linked to 
deficiencies in NO production and availability caused, in part, by dietary NO synthase 
inhibition. 
 
Keywords:  hypertension, nitric oxide, obese Zucker rat, diet-induced, high fat 
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Introduction 
The prevalence of obesity has recently skyrocketed in the United States and other 
industrialized countries.  According to the National Health and Nutrition Examination 
Studies (NHANES), the prevalence of obesity, defined as a body mass index equal to or 
greater than 30 kg/m2, more than doubled among adults in the United States from 1980 to 
2000 (Flegal et al., 2002).  The rise in the prevalence of obesity is a chief factor in the 
increasing incidence of hypertension (Care, 2005) and other obesity-related disorders 
such as coronary heart disease (Pi-Sunyer, 2002).  According to risk estimates from the 
Framingham Heart Study, obesity is linked to about 75% of male and about 65% of 
female cases of hypertension (Davy and Hall, 2004; Garrison et al., 1987).  Thus, 
obesity-hypertension appears to be the most common form of essential hypertension. 
 
Meaningful advances in the field of obesity-hypertension depend upon the development 
of an assortment of animal models that have characteristics in common with those 
observed in obesity-hypertension in humans.  Thus far, several very good models of 
obesity-hypertension have been developed using rats (Ernsberger et al., 1999b), dogs 
(Rocchini et al., 1987), and rabbits (Carroll et al., 1996).  Still, the field may benefit from 
additional animal models because of the complex polygenic nature of obesity-
hypertension.  This view is further reinforced by the observation that factors commonly 
clustering with obesity (e.g. insulin resistance) that may play a role in promoting 
hypertension are not uniformly present in obese hypertensives.  At this juncture, it 
appears that the most practical approach to the study of obesity-hypertension would be to 
use a wide range of species/models. 
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The obese Zucker rat (OZR), which is used extensively as a model of metabolic 
syndrome X (Takaya et al., 1996), is also considered by some to be a viable model for 
obesity-associated hypertension (Kurtz et al., 1989).  Controversy exists, however, as to 
whether the OZR is actually hypertensive.  Some investigators have reported that the 
OZR is not hypertensive relative to age- and gender- matched lean Zucker rats (Bunag 
and Barringer, 1988; Morgan et al., 1995; Pamidimukkala and Jandhyala, 1996; Pawloski 
et al., 1992; Reddy and Kotchen, 1992), whereas others have indicated that the OZR is 
hypertensive (Alonso-Galicia et al., 1996; Ambrozy et al., 1991; Carlson et al., 2000; 
Kurtz et al., 1989; Maher et al., 1995; Turner et al., 1995).  In those studies where 
hypertension was present, it was generally mild.  The argument that the obese Zucker rat 
is at a greater risk of developing hypertension has been bolstered by experiments from 
our laboratory showing that obese rats are far more sensitive to deoxycorticosterone-salt-
induced hypertension than lean rats of the same age and gender (Morrison et al., 2002). 
 
Models of obesity that are based on dietary manipulations, such as increased fat 
consumption, have been suggested to be particularly applicable to understanding human 
obesity (Lauterio et al., 1994).  In addition to promoting obesity, high dietary fat 
consumption per se may be independently associated with hypertension.  For example, in 
the Dietary Approaches to Stop Hypertension (DASH) clinical trials, patients’ blood 
pressures were lowered in the absence of weight loss by reducing the dietary content of 
saturated fat (Delichatsios and Welty, 2005).   Furthermore, high fat diets promote insulin 
resistance, a condition implicated in the pathogenesis of hypertension, independently of 
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obesity in animal models (Vessby, 2003; Woods et al., 2004).   Still, it is not clear 
whether high fat diets interact with obesity to promote hypertension.  In part, this lack of 
understanding is due to a very close and confounding relationship between high fat diets 
and weight gain. 
 
Another dietary factor which has received considerable scrutiny regarding its role in 
hypertension is sodium chloride.  Increased dietary salt consumption induces 
hypertension in salt-sensitive, but not salt-resistant individuals (Facchini et al., 1999).  
Since salt-sensitivity occurs at a much higher rate in obese individuals, obesity-
hypertension is thought by some to be a salt-sensitive form of hypertension (Diaz, 2002; 
Rocchini, 2000).  There are many hypotheses that have been proposed to explain the link 
between salt-sensitivity and hypertension.  One hypothesis, based on studies using both 
human subjects and laboratory animals, suggests that salt-sensitivity of blood pressure 
can be explained, at least in part, by an inability of the salt-sensitive subject to sustain or 
increase NO production in response to high salt intake (Bragulat and de la Sierra, 2002; 
Cubeddu et al., 2000; Kopkan and Majid, 2005; Manning et al., 2001).  NO plays an 
important role in the long term regulation of blood pressure through its effects on the 
kidney:  it mediates the tubuloglomerular feedback response to luminal sodium, renal 
blood flow, and pressure natriuresis (Bachmann and Mundel, 1994; Cowley et al., 2003; 
Raij and Baylis, 1995). 
 
The objective of the present study was to further evaluate the obese Zucker rat as a model 
of obesity-hypertension by exposing it to dietary factors that may promote hypertension.  
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Lean and obese Zucker rats were fed a high fat diet that was later supplemented with salt 
in the drinking water, in order to investigate whether obese rats were more inclined to 
develop hypertension on this diet than lean rats.  Our experiments indicate that (1) obese 
Zucker rats develop marked hypertension in response to a high fat, salt-supplemented 
diet, whereas lean Zucker rats do not (2) NO production and availability may be reduced 
by a high fat diet, and (3) the resulting NO deficiency may be due, in part, to decreased 
NO synthase activity. 
 
Methods 
Animals.  Seven-week-old female lean (Fa/?) and obese (fa/fa) Zucker rats were 
purchased from Charles River Laboratories (Wilmington, MA, USA) and allowed to 
acclimate to the Marshall University Animal Resources Facility for one week prior to the 
start of an experiment.  The rats were housed in plastic cages with corn chip bedding in a 
room having a 12 h light/dark cycle and maintained at an ambient temperature of 23±2 
°C. All procedures using animals were reviewed and approved by the Marshall 
University Institutional Animal Care and Use Committee. 
 
Experimental protocol.  Systolic blood pressure (SBP) was measured once weekly using 
tail cuff plethysmography.  Recordings were taken with a programmed 
electrosphygmomanometer coupled to a pneumatic pulse transducer and tail cuff (Narco-
Biosystems, Houston, Texas, USA).   
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Food consumption, water consumption, and 24-hour urine output were measured weekly 
by placing rats in stainless steel metabolic cages. The rats were given 24 hours to adapt to 
the cages before measurements were taken or urine was collected. To help ensure a 
consistent environment, the metabolic cages were placed in the same room in which the 
rats were normally housed.  After the 24-hour urine collection, the urine was centrifuged 
to remove any particulate matter.  Aliquots of the supernatant were then stored at -20oC 
until used for analysis. 
 
After basal measurements were obtained (week 0), the rats were divided into four groups.  
One group of lean rats and one group of obese rats were maintained on a standard 
balanced rodent diet (Rodent Diet 5001) for the duration of the experiment and one group 
of lean rats and one group of obese rats were fed a high fat diet (formula D12266B: 
Research Diets, New Brunswick, New Jersey, USA) during the same 10 week interval.  
The high fat diet (Table 4.1) was the purified ingredient-version of the condensed milk 
diet that is used to separate lean from obesity-prone outbred rats (Lauterio et al., 1994). 
After 4 weeks, 1% NaCl was added to the drinking water of all four groups until the end 
of the experiment.  At the end of the experiment, the rats were euthanized by 
exsanguination via cardiac puncture after being deeply anesthetized with an 
intraperitoneal injection of ketamine HCl:xylazine (45:5 mg/kg).  Blood was drawn into 
heparinized syringes and the plasma was recovered by centrifugation and stored at -20oC 
until used for analysis.  After the rats were exsanguinated, their kidneys were removed 
and homogenized in ice-cold EDTA-free homogenization buffer (50 mM phosphate 
buffer, pH 7.5, containing 250 mM sucrose, 10 µg/ml aprotinin, 1 µg/ml leupeptin, and 
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87 µg/ml phenylmethylsulfonylfluoride) using Duall glass homogenizers.  The 
homogenate was then centrifuged to remove cellular debris and the resultant supernatant 
was stored at -70oC until used for analysis. 
 
Analytical techniques.  Plasma insulin and leptin levels were determined using [125I] rat 
insulin and leptin radioimmunoassay kits according to the manufacturer’s instructions 
(Linco, St. Charles, MO, USA).  Nitric oxide production was estimated by measuring the 
concentration of NO3 + NO2 in the urine with a nitric oxide quantitation kit (Active 
Motif, Carlsbad, CA, USA).  Total nitric oxide synthase (NOS) activity in whole kidney 
homogenates was determined in duplicate using an assay kit (Cayman Chemical, Ann 
Arbor, MI, USA) that measures the conversion of L-[3H] arginine to [3H] citrulline.  
Reaction conditions were verified using 1 mM NG-nitro-L-arginine as a negative control.  
All samples were measured in duplicate.     
 
Statistics.  Data is expressed as means ± SE.  Statistical differences among means were 
determined by two-way analysis of variance (2WANOVA) followed by a Tukey test.  In 
the case of leptin, multiple t-tests were subsitituted for 2WANOVA because the obese 
and lean data sets were too unbalanced for ANOVA comparison.  Differences were 
determined to be statistically significant at p≤0.05.   Statistical analysis was performed 
using SigmaStat software (Jandel Scientific Software, San Rafael, CA, USA).   
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Results 
Consumption of a high fat diet induced a greater weight gain than a standard balanced 
rodent diet in both lean and obese rats, with the weight gain in obese rats being 
considerably larger than that of lean rats (Fig. 4.1A).  Despite substantial weight gain, 
obese rats consuming a high fat diet had a reduced cumulative energy intake (CEI) 
relative to obese rats on the standard control diet (Fig. 4.1B).  We also observed that the 
high fat diet did not affect the cumulative energy intake of lean animals. In addition, 
obese rats on either diet had a greater energy efficiency ratio than lean rats fed the same 
diet (the energy efficiency ratio measures how efficiently energy is converted to body 
weight). This difference in energy efficiency ratios between lean and obese rats was 
particularly noticeable when comparing rats on the high fat diet (Fig 4.1C).    
 
Regardless of diet, plasma leptin and insulin levels were markedly elevated in obese rats 
relative to lean rats by the time blood samples were obtained at the end of the study (Fig. 
4.2).  The high fat diet, however, had no effect on leptin levels in obese rats which is in 
contrast to the significant rise in plasma leptin levels observed in lean rats on the high fat 
diet (Fig. 4.2A).  Conversely, plasma insulin levels were unaffected by the high fat diet in 
lean rats, whereas they were significantly elevated in obese animals on the same diet (Fig. 
4.2B).   
 
A principal objective of this study was to determine whether obesity increases the risk of 
developing salt-sensitive-hypertension in animals consuming a high fat diet.  Both lean 
and obese rats were fed either a high fat diet or a diet of standard rat chow for the 
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duration of the study.  Four weeks into the study, 1% NaCl was added to the drinking 
water of all animals. Within 2 weeks of adding NaCl to the drinking water, the obese rats 
on the high fat diet developed moderate hypertension (Fig. 4.3A).  The peak systolic 
blood pressure for obese rats on the high fat, salt-supplemented diet was 158 mm Hg.  
From the 6th week until the end of the study, the blood pressures of obese rats on the high 
fat, salt-supplemented diet were significantly higher than those of obese rats on the salt-
supplemented control diet (Fig. 4.3A).  By contrast, the blood pressures of lean rats were 
hardly affected by dietary manipulation.  Average blood pressures of lean rats on a high 
fat, salt-supplemented diet never rose above 136 mm Hg, and only at one point was the 
elevation in blood pressure statistically significant (Fig. 4.3B).   
 
To test the hypothesis that a diminished capacity to produce nitric oxide (NO) is involved 
in the development of hypertension in obese rats on the high fat, salt-supplemented diet, 
urinary excretion of stable NO metabolites (NO2 and NO3) was measured in all the 
treatment groups before and after salt supplementation.  As shown in Figure 4.4, obese 
Zucker rats on the control diet excreted significantly more stable NO metabolites (NOx) 
than their lean counterparts on the same diet.  Also, there was an increase in NOx 
excretion in both lean and obese rats when the control diet was supplemented with NaCl 
(Figure 4.4).  This increase in NOx excretion was particularly striking in obese rats on the 
control diet.   
 
Results of this study also show that the high fat diet suppresses NOx excretion (Figure 
4.5A).  Again, the effect in obese rats is quite dramatic because of the pronounced rise in 
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urinary NOx excretion associated with an increased NaCl load.  To test the hypothesis 
that the decrease in NOx excretion by rats on the high fat diet is due, at least in part, to a 
decrease in NO production, renal NO synthase activity was measured in whole kidney 
homogenates obtained from week 10 animals. There was a significant suppression of NO 
synthase activity in renal homogenates from obese rats on the high fat, salt-supplemented 
diet relative to the obese control group (Fig. 4.5B).  Renal NO synthase activity levels in 
lean control, lean high fat, and obese control animals were similar. 
 
 
 
Discussion 
The objective of the present study was to evaluate the obese Zucker rat as a model of 
obesity-associated hypertension using a high fat, salt-supplemented diet to induce 
hypertension.  Obese rats that were fed the high fat diet developed hypertension when 
subjected to a salt load whereas lean rats did not.  Moreover, blood pressures did not go 
up in response to a salt load in either the lean or obese rats that were fed a diet of standard 
rat chow.  These results suggest that obesity increases the risk of developing hypertension 
when the obese subject is exposed to a hypertensive challenge.  This observation is 
consistent with previous work in which we demonstrated that the obese Zucker rat was 
more sensitive to DOCA-salt-induced hypertension than age- and gender-matched lean 
rats (Morrison et al., 2002). 
 
Blood pressures in the obese rats that were fed the high fat, salt supplemented diet 
reached a plateau within a few weeks of being subjected to a salt load with the peak 
blood pressure reaching 158 ± 4 mmHg.  There was no overt evidence of renal damage at 
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the end of the study and the practically all animals survived.  Thus, this model of obesity-
hypertension could prove to be a useful model for studying long-term effects of moderate 
hypertension.  This model may also be particularly useful for studying the interaction of 
obesity and hypertension on renal function since both hypertension (Morrison et al., 
2005; Morrison et al., 2002) and obesity (Kasiske et al., 1985; Magil, 1995; Shimamura, 
1983) affect renal function in the Zucker rat. 
 
The moderate hypertension induced by a high fat, salt-supplemented diet stands in sharp 
contrast to the severity of the response of the obese Zucker rat to DOCA-salt-induced 
hypertension.  In the DOCA-salt model, a significant elevation in blood pressure was 
evident within 4 days of the onset of treatment.  The blood pressure peaked at levels in 
excess of 195 mmHg.  The mortality rate was high and histological analysis revealed an 
end-stage kidney (Morrison et al., 2005).  Because of the high mortality rate, the DOCA-
salt model is only useful for short-term studies. 
 
There is substantial evidence that the sensitivity of blood pressure to sodium intake may 
be modulated by a variety of nutritional factors (Kotchen and Kotchen, 1997). In 
particular, high fat diets have been shown to promote sodium and water retention 
(Strazzullo et al., 2001).  In the present study, the obese Zucker rat appears to exhibit 
diet-induced salt-sensitivity of blood pressure in response to a high fat diet.  The blood 
pressure did not rise appreciably in obese rats on the high fat diet during the 4 week 
interval prior to being subjected to a salt load.  This is consistent with the observations of 
Alavi et al. (1995) and Maher et al. (1995).  When subjected to a salt load, blood pressure 
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rose in the obese Zucker rat on a high fat diet, but hardly changed in obese rats on a diet 
of standard rat chow.    
 
One mechanism through which high fat diets may promote salt-sensitivity involves the 
disruption of renal NO function.  NO plays an important role in the long term regulation 
of blood volume and pressure through its effects on the kidney.  NO mediates the 
tubuloglomerular feedback response to luminal sodium, renal blood flow, and pressure 
natriuresis (Bachmann and Mundel, 1994; Cowley et al., 2003; Raij and Baylis, 1995).  
Furthermore, NO has well known vasodilatory properties in the vasculature (Cockcroft, 
2005).  Studies in laboratory animals and humans have suggested that salt-sensitivity of 
blood pressure can be at least partly explained by an inability to sustain or increase NO 
production in response to high salt intake (Cubeddu et al., 2000; Kopkan and Majid, 
2005; Manning et al., 2001).  Thus, increased production of NO appears to be a vital 
physiological response for homeostatic management of blood pressure and volume under 
conditions of increased salt consumption.  Accordingly, NO metabolite excretion was 
markedly increased after salt supplementation, reflecting increased systemic nitric oxide 
production in response to sodium loading.   Interestingly, obese Zucker rats on the control 
diet exhibited higher systemic NO production than lean counterparts both before and after 
salt supplementation, suggesting that this mechanism may be playing a greater regulatory 
role in the obese rat than in the lean rat.  Ingestion of the high fat diet markedly reduced 
this effect, suggesting that it has a negative impact on systemic NO production.  This 
potential inhibitory effect of a high fat diet on NO production is also evidenced to a lesser 
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extent in the lean Zucker rats, where NOx excretion was reduced slightly, but 
significantly. 
 
The phenotypic differences in physiologic responses to salt loading were further 
investigated by directly measuring NO production in the kidney, where NO may play a 
critical role in the chronic regulation of sodium retention and blood pressure (Cowley et 
al., 2003).  Renal NOS activity was reduced by the high fat diet in obese rats, but lean 
rats were unaffected by the dietary modification, further demonstrating the increased 
susceptibility of obese rats to diet-induced dysregulation of nitric oxide production.  
These data suggest the effects of the high fat diet on nitric oxide production may promote 
salt-sensitivity of blood pressure in obese Zucker rats. 
 
The high fat diet significantly reduced urinary NO metabolite excretion in lean animals 
by the end of the study, but it had no effect on renal NO production at this point.  This 
underscores the complexity of NO metabolism and the importance of other mechanisms 
that ultimately may play a role in determining NO availability, such as the inactivation of 
NO by oxidative stress.  Recent studies have indicated that oxidative stress may rapidly 
inactivate NO, reducing functional NO availability (Dobrian et al., 2003; Roberts et al., 
2003).   
 
The underlying cause of obesity in obese Zucker rats is a missense point mutation in the 
leptin receptor (Chua et al., 1996) that leads to severe leptin resistance and 
hyperleptinemia.  In our study, the high fat diet did not further exaggerate this 
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genetically-produced hyperleptinemia in OZRs, despite significant diet-induced weight 
gain, suggesting that plasma leptin may have already achieved peak levels in response to 
the aforementioned receptor defect.   On the other hand, leptin levels were increased 
more than five-fold after high fat feeding in lean Zucker rats, which have a normally 
functioning leptin receptor.  These phenotypic differences in leptin physiology may be 
responsible, in part, for the divergence of blood pressure responses between lean and 
obese rats on the experimental diet.  Villarreal et al. (1998) have demonstrated a 
significant natriuretic effect of exogenous leptin that is attenuated in obese Zucker rats, 
suggesting that the genetically determined inability to respond to leptin in the obese 
Zucker rat may lead to impaired natriuretic capacity.  This impairment may promote salt-
sensitivity of blood pressure in obese Zucker rats.  In contrast, lean rats with their 
functioning leptin receptor may be able to maintain salt resistance.  In addition to this 
potential role in maintaining resistance to salt, a role for leptin-induced release of NO in 
maintaining normal blood pressure homeostasis has also been suggested (Fruhbeck, 
1999). 
 
In conclusion, our data indicates that high dietary fat intake dramatically compounds salt-
sensitivity of blood pressure in genetically obese Zucker rats.  This sensitivity is closely 
correlated to derangements in the compensatory production of NO, which is inhibited by 
high fat feeding in obese Zucker rats.   In addition, leptin is implicated as a potential 
mediator in the dysregulation of blood pressure in obese Zucker rats on a moderately high 
fat, salt-supplemented diet.  Taken together, the data suggests that multiple factors are 
probably responsible for the salt-sensitivity of blood pressure in Zucker rats. 
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Figures and Tables 
 
 
Table 4.1.  Energy composition of the control 
and high fat diets.  Macronutrient components 
are given in kcal percentage. 
 
Diet Control High Fat 
 
 
Protein 23 17 
Carbohydrate 65 52 
Fat 12 32 
 
 
   
Total kcal/g 4.00 4.41 
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Figure 4.1.  Weight gain (A), cumulative energy intake (B) and energy efficiency ratio (C) for lean 
and obese Zucker rats that were fed a high fat diet or standard balanced rodent (control) diet ad 
libitum.  LC = lean rats, control diet; LHF = lean rats high fat diet; OC = obese rats, control diet; 
and OHF = obese rats, high fat diet. The cumulative energy intake (CEI) and energy efficiency ratio 
(EER) were calculated as described in the methods. The number of rats per group: LC =17, LHF = 
17, OC = 16 and OHF = 14.  *p<0.05 for a diet comparison within a given phenotype; +p<0.05 for a 
phenotype comparison within a given dietary treatment. 
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Figure 4.2.  Plasma leptin (A) and insulin (B) concentrations in lean control (LC), lean high fat 
(LHF), obese control (OC) and obese high fat (OHF) groups after 10 weeks of dietary treatment. The 
number of rats per group: 7 for LHF and n=8 for all other groups. *p<0.05 for a diet comparison 
within a given phenotype; +p<0.05 for a phenotype comparison within a given dietary treatment.   
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Figure 4.3.  Blood pressures of obese (A) and lean (B) Zucker rats on either a high fat or control diet.  
All rats were being fed a control diet when blood pressures were obtained at week zero.  Immediately 
after week zero measurements were recorded, half of the lean and obese rats were placed on a high 
fat diet (indicated by first arrow).  After blood pressure measurements were recorded at week 4, the 
drinking water of all groups was supplemented by 1% saline (indicated by second arrow). The 
number of rats per group: 16 for obese groups and 18 for lean groups.  *p<0.05 for comparison of 
dietary treatment within the same phenotype at the same week. 
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Figure 4.4. NOx (NO2 plus NO3) excretion by lean control (LC) and obese control (OC) groups on 
weeks 4 and 10.  The number of rats per group: 9 for lean groups and 8 for obese groups.  *p<0.001 
for diet comparisons within a given phenotype at the same week; +p<0.05 for a phenotype 
comparison within a given dietary treatment at the same week.   
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Figure 4.5.  NOx excretion and renal nitric oxide synthase (NOS) activity in lean control (LC), lean 
high fat (LHF), obese control (OC), and obese high fat (OHF) groups after 10 weeks of treatment.  
Number of rats per group: 7 for LHF and n=8 for all other groups. *p<0.05 for a diet comparison 
within a given phenotype; +p<0.05 for a phenotype comparison within a given dietary treatment.   
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CHAPTER V 
 
Conclusions and Future Directions 
 
 
Conclusions 
We have characterized two models of obesity-hypertension using the obese Zucker rat.  
Both models have the potential to yield new insights into the nature of obesity-
hypertension and may be useful in developing a better understanding of this complex 
disease.  In one model, hypertension was induced by the administration of 
deoxycorticosterone acetate (DOCA) and salt excess.  DOCA induces salt retention and a 
volume-expansion-dependent form of hypertension.  The hypertensive response was 
clearly exacerbated in obese rats relative to age- and gender-matched lean controls that 
were subjected to the same treatment regimen.  The DOCA-salt treated obese Zucker rat 
(DST-OZR) rapidly advanced to a state of severe hypertension and exhibited signs of end 
stage kidney disease by the end of the study (Morrison et al., 2005).  By six weeks, the 
mortality rate in DST-OZRs climbed dramatically, making this model unsuitable for 
longer-term investigations.  The second model of obesity-hypertension involved feeding 
rats a high fat diet and then subjecting them to a salt load.  In this model, a more 
moderate form of hypertension with a lower mortality rate (Morrison et al., 2002) and 
less noticeable renal damage (personal communication, Dr. Betts Carpenter) developed in 
the obese Zucker rat.  In contrast, the response of lean rats to this treatment was marginal 
and statistically insignificant.  While few DST-OZRs survived more than 6 weeks beyond 
the onset of treatment, HF-OZRs had barely developed hypertension by that point; 
moreover, practically all HF-OZRs survived the 10-week long experimental treatment 
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(n=32, data not shown).  An impaired ability to respond to a salt load appears to be a 
common characteristic of both of these models of obesity-hypertension.  This may be a 
useful feature of these models since dietary salt consumption has been linked to human 
hypertension in general  (MacGregor, 1983; MacGregor et al., 1989) and obesity-
associated hypertension (Hsueh and Buchanan, 1994) in particular.   
 
One aim of this research was to investigate a probable mechanism that could promote the 
development of hypertension in the HF-OZR model.  In this regard, our work indicates 
that a dysfunction in the nitric oxide pathway may play a role in the pathophysiology of 
obesity-hypertension in the HF-OZR.  Results presented as part of this dissertation 
clearly indicate that NO production is markedly suppressed by the high fat diet and that 
this effect is due, in part, to the inhibition of NO synthase activity.  In light of the 
dramatic increase in NO production by obese rats that remain normotensive when 
subjected to a salt load while on a standard control diet, the inhibition of NO synthase by 
a high fat diet may indeed be a critical component of the mechanism underlying the 
development of hypertension in this model. 
 
Future Directions 
Future investigations will attempt to further elucidate the roles of genetic and 
environmental factors in the HF-OZR.  Gene microarray analysis of cortical kidney 
homogenates from HF-OZR rats has already been performed, providing semiquantitative 
comparisons of the expression levels of over 9000 genes.  Eventually, this data will be 
probed using a sophisticated technique known as gene set enrichment analysis (GSEA), 
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which allows the detection of cumulative changes in gene expression throughout multiple 
a priori defined biological pathways (Curtis et al., 2005).  This analysis could provide a 
more comprehensive view of the mechanisms that may promote hypertension in response 
to a high fat diet and genetic obesity.  Moreover, experiments can be designed to 
investigate whether the pathways that are implicated by the GSEA analysis may be 
involved in the pathogenesis of obesity-hypertension.   
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APPENDIX B  
Cortical Kidney Microarray in HF-OZR 
 
Methods:  At the end of the high fat dietary study, whole kidneys were excised and flash-
frozen in liquid nitrogen.  Frozen kidneys were stored at -70 ºC until thawed on 
RNAlater®-ICE according to the manufacturer’s instructions (Ambion, USA).  Cortical 
kidneys were excised and total RNA was extracted using RNEasy MIDI kit (Qiagen, 
USA).  RNA integrity was assessed using the Agilent Bioanalyzer® (Agilent 
Technologies, Palo Alto, CA).  40 µg total RNA for 4 biological repeats per experimental 
group were used in a balanced block experimental design with a MWG rat 10K array 
(MWG, UK).  Superscript Direct cDNA Labeling for Microarray (Invitrogen, USA) was 
used for labeling.  mRNA samples were fluorescently labeled by incorporating Cy3-
dCTP or Cy5-dCTP (Perkin-Elmer, USA) during reverse transcription.  Hybridization 
was done on Hybe Station (Genomic Solutions, USA).  Microarrays were scanned using 
ScanArray Express and quantified with ScanArray Express Software (Perkin-Elmer, 
USA), and then analyzed with Genespring Software (Agilent, USA). 
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Obese High Fat vs. Obese Control Diet     
 
 
    
GENE ID FOLD DESCRIPTION 
 INCREASE 
 
D26111_1 2.06 chloride channel putative; clc-k2s; clc-k2l 
 
RATTUS01236 2.16 expression: liver kidney heart brain strains: shrsp wistar_kyoto 
trembl||q9jmf4 ; complete cds; clone:2-31 
 
RATTUS01691 2.50 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak018016|ak018016_1 riken full-length 
enriched library; clone:5830455m19 - mus musculus 
 
RATTUS01645 2.51 expression: kidney strains: shrsp wistar_kyoto trembl||q9qxp0 rh 
type c glycoprotein 
 
NM_033349_1 2.71 expression: liver kidney strains: sprague_dawley wistar_kyoto 
gbp|u97667|u97667_1 rsp29 - rattus norvegicus; hydroxyacyl 
glutathione hydrolase hagh 
 
NM_030833_1 2.73 interferon-inducible protein 16 loc80875 
 
RATTUS00354 3.06 expression: liver brain heart kidney strains: shrsp 
sprague_dawley wistar_kyoto trembl||q9nwu5 cdna flj20594 fis; 
clone kat08731 
 
X62660_1 3.17 glutathione transferase 
 
NM_052802_1 3.34 kidney androgen-regulated protein kap 
 
RATTUS01543 3.60 expression: liver heart strains: sprague_dawley wistar_kyoto 
gbp|ak012051|ak012051_1 riken full-length enriched library; 
clone:2610319b19 - mus musculus 
 
RATTUS02152 3.78 expression: brain kidney strains: shrsp 
gbp|ak027689|ak027689_1 cdna flj14783 fis; clone 
nt2rp4000541 unnamed protein product - homo sapiens 
 
RATTUS00919 4.73 expression: liver brain strains: shrsp sprague_dawley 
wistar_kyoto trembl||o88783 coagulation factor v 
 
RATTUS01707 4.76 expression: kidney strains: wistar_kyoto 
gbp|ak003647|ak003647_1 riken full-length enriched library; 
clone:1110012o14 - mus musculus 
    
    
GENE ID FOLD DESCRIPTION 
 DECREASE 
    
NM_020976_1 2.05 kidney-specific membrane protein nx-17 
 
U00926_1 2.08 delta subunit of f1f0 atpase 
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M36410_1 2.13 sepiapterin reductase ec 1.1.1.153 
 
NM_017081_1 2.16 hydroxysteroid dehydrogenase; 11 beta type 2 hsd11b2; 11-
beta-hydroxylsteroid dehydrogenase 
 
AF029886_1 2.17 microphthalmia associated transcription factor microphthalmia 
 
NM_017314_1 2.25 polyubiquitin ubc; ubiquitin c 
 
NM_017314_1 2.29 polyubiquitin ubc; ubiquitin c 
 
NM_022399_1 2.34 d-beta-hydroxybutyrate dehydogenase; calreticulin; calr; 
precursor aa -17 to 399 
 
NM_031090_1 2.44 ras-related protein rab1; ras 
 
NM_053576_1 2.44 acidic calcium-independent phospholipase a2 aipla2; thiol-
specific antioxidant protein prdx5; tsa 
 
M96377_1 2.58 neurexin ii-beta-a 
 
S61973_1 2.64 nmda receptor glutamate-binding subunit 
 
RATTUS01564 2.64 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak009057|ak009057_1 riken full-length 
enriched library; clone:2310001a20 - mus musculus 
 
RATTUS01409 2.67 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|af195142|af195142_1 selenoprotein r - mus 
musculus 
 
NM_017245_1 2.76 eukaryotic translation elongation factor 2 eef2; ef-2; aa 1-858 
 
RATTUS02428 2.87 expression: brain strains: shrsp sprague_dawley wistar_kyoto 
mwg own new gene sequence 
 
NM_031012_1 3.02 kidney zn-peptidase precursor; aminopeptidase m apm; anpep 
 
NM_017147_1 3.21 cofilin 1; non-muscle cfl1 
 
NM_031354_1 3.24 mitochondrial voltage dependent anion channel vdac2; voltage-
dependent 2 
 
S78284_1 3.27 bcl-x short form; bcl-xshort; bcl-x-long; bcl-xalpha 
 
NM_012783_1 3.31 basigin ox47 antigen or ce-9 emmprin in human neurothelin; ht7 
or 5a11 in avian bsg; mrc; transmembrane glycoprotein 
 
RATTUS00028 3.40 expression: heart brain strains: shrsp sprague_dawley 
wistar_kyoto gbp|ab055737|ab055737_1 nd1-l kelch family 
protein nd1-l - mus musculus 
 
NM_053840_1 3.56 put. ggt light subunit 380-568 protein sequence is in conflict with 
the conceptual translation; gamma-glutamyl transpeptidase ec 
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2.3.2.2; m33821; precursor aa 4-568; gamma-
glutamyltranspeptidase 1-568 
 
NM_013013_1 3.68 prosaposin sulfated glycoprotein; sphingolipid hydrolase 
activator psap; glycoprotein precursor; glycoprotein-1 
glycoprotein-1; sgp-1; prosapo>; prosaposin; sgp-1 
 
NM_023950_1 4.19 rab7; member ras oncogene family rab7; gtp-binding protein; 
ras-related p23 
 
NM_017173_1 4.26 serine proteinase inhibitor; clade h heat shock protein 47; 
member 1 serpinh1; collagen-binding gp46 
 
NM_020076_1 4.28 3-hydroxyanthranilate 3;4-dioxygenase haao 
 
NM_031605_1 4.44 cytochrome p450; 4a10 cyp4a10; p450 
 
NM_022866_1 4.68 sodium-dependent high-affinity dicarboxylate transporter 3 
nadc3; sdct2 
 
NM_024149_1 4.96 adp-ribosylation factor 5 arf5 
 
S69315_1 6.51 endoplasmin grp94 
 
RATTUS00063 11.31 expression: liver brain heart kidney strains: shrsp 
sprague_dawley wistar_kyoto gbp|x02344|x02344_1 beta 2 
beta-tubulin - homo sapiens; trembl||q9jjy6 fragment 
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GENE ID FOLD DESCRIPTION 
 INCREASE 
     
D16478_1 2.05 mitochondrial long-chain enoyl-coa hydratase/3-hydroxycyl-coa 
dehydrogenase alpha-subunit rtp-alpha 
 
NM_052802_1 4.16 kidney androgen-regulated protein kap 
     
     
     
GENE ID FOLD DESCRIPTION 
 DECREASE 
     
     
AJ238391_1 2.06 sulfotransferase k1 sultk1; k2 sultk2 
 
NM_053864_1 2.10 transitional endoplasmic reticulum atpase; valosin-containing 
protein vcp 
 
RATTUS03589 2.12 expression: brain strains: shrsp sprague_dawley trembl||q9nsn1 
hypothetical 110.4 kda protein fragment 
 
RATTUS00172 2.14 expression: kidney heart brain strains: shrsp sprague_dawley 
wistar_kyoto gbp|m74773|m74773_1 spnb-2 brain beta spectrin 
- mus musculus 
 
NM_012504_1 2.20 atpase; na+k+ transporting; alpha 1 polypeptide atp1a1; na+;k+-
atpase alpha-subunit precursor; na+ and k+ catalytic subunit; 
na;k-atpase alpha-1; atpase aa -4 to -1 
 
NM_053837_1 2.21 rat assembly protein ap50 associated with clathrin-coated 
vesicles; adaptor-related complex 2; mu 1 subunit ap2m1 
 
NM_053576_1 2.28 acidic calcium-independent phospholipase a2 aipla2; thiol-
specific antioxidant protein prdx5; tsa 
 
RATTUS02848 2.31 expression: kidney heart strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak010581|ak010581_1 riken full-length 
enriched library; clone:2410024g15 - mus musculus; 
gbp|u51014|u51014_1 pep4 prolidase 
 
NM_017233_1 2.32 4-hydroxyphenylpyruvic acid dioxygenase hpd; 4-
hydroxyphenylpyruvate hppd; f alloantigen 
 
NM_053752_1 2.41 succinate-coa ligase; gdp-forming; alpha subunit suclg1; 
succinyl-coa synthetase ec 6.2.1.4 
 
NM_022399_1 2.60 d-beta-hydroxybutyrate dehydogenase; calreticulin; calr; 
precursor aa -17 to 399 
 
AF029886_1 2.78 microphthalmia associated transcription factor microphthalmia 
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NM_019134_1 2.86 solute carrier family 12; member 1 bumetanide-sensitive sodium-
[potassium]-chloride cotransporter slc12a1; sodium- potassium –
chloride 
 
U30290_1 3.05 galanin receptor galr1 
 
NM_012615_1 3.09 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
NM_021594_1 3.32 erm-binding phosphoprotein loc59114 
 
S61973_1 3.33 nmda receptor glutamate-binding subunit 
 
NM_013085_1 3.46 urinary plasminogen activator; urokinase plau; urikinase-type 
activator; upa 
 
NM_021266_1 3.55 drosophila polarity gene frizzled homologue fzd1 
 
RATTUS00794 3.66 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak007469|ak007469_1 riken full-length 
enriched library; clone:1810013b01 - mus musculus 
 
RATTUS00028 3.67 expression: heart brain strains: shrsp sprague_dawley 
wistar_kyoto gbp|ab055737|ab055737_1 nd1-l kelch family 
protein nd1-l - mus musculus 
 
NM_021740_1 3.86 alpha-prothymosin myc-regulated gene; prothymosin precursor; 
prothymosin-alpha; alpha ptma 
 
RATTUS03021 4.56 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|bc003903|bc003903_1 glutathione s-
transferase theta 1 - mus musculus 
 
M24359_2 5.33 m2 pyruvate kinase pk 
 
NM_012886_1 5.70 tissue inhibitor of metalloproteinase 3 timp-3; timp3 
 
Z11994_1 6.36 45kda protein 
 
NM_013214_1 6.72 cytosolic peroxisome proliferator-induced acyl-coa thioesterase; 
hydrolase rbach; rlach1; acyl coenzyme a thioester 
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GENE ID FOLD DESCRIPTION 
 INCREASE 
 
NM_012939_1 2.12 cathepsin h pre-pro-peptide; rch11; ctsh 
      
AJ309926_1 2.19 ion channel asic 1b; asic-beta  
       
NM_020976_1 2.24 kidney-specific membrane protein nx-17 
      
S76779_1 2.25 apolipoprotein e rapoe; apoe  
       
NM_031012_1 2.30 kidney zn-peptidase precursor; aminopeptidase m apm; anpep 
    
M35052_1 2.55 f-0-atpase subunit b precursor  
       
RATTUS00729 2.56 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak004817|ak004817_1 riken full-length 
enriched library; clone:1200017c17 - mus musculus 
 
RATTUS01564 2.63 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak009057|ak009057_1 riken full-length 
enriched library; clone:2310001a20 - mus musculus 
 
M36410_1 2.72 sepiapterin reductase ec 1.1.1.153 
      
RATTUS01409 2.80 expression: liver brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|af195142|af195142_1 selenoprotein r - mus 
musculus 
   
NM_022266_1 2.80 connective tissue growth factor ctgf 
      
RATTUS00443 2.90 expression: heart brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|aj310346|aj310346_1 paf67 67 kda 
polymerase-associated factor paf67 - mus musculus 
 
NM_031031_1 3.33 l-arginine: glycine amidinotransferase gatm; l-arginine:glycine 
    
NM_021757_1 3.45 pleiotropic regulator 1 plrg1  
       
RATTUS00249 3.51 expression: liver heart kidney brain strains: shrsp 
sprague_dawley wistar_kyoto trembl||caa02861 sequence 56 
from patent wo9520654 
  
NM_022947_1 3.52 suppressor of k+ transport defect 3 skd3  
      
NM_017306_1 4.40 dodecenoyl-coenzyme a delta isomerase 3;2 trans-enoyl-
coenyme a isomerase dci; delta-3;delta-2-enoyl-coa; 3-2trans-
enoyl-coa 
   
NM_053314_1 4.54 potassium inwardly-rectifying channel; subfamily j; member 16 
kcnj16; kir5.1; inward rectifier potassuim channel 9 
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NM_031605_1 5.63 cytochrome p450; 4a10 cyp4a10; p450  
      
NM_013098_1 17.43 glucose-6-phosphatase catalytic subunit g6pase; g6pc   
         
         
         
 
GENE ID FOLD DESCRIPTION 
 DECREASE         
         
RATTUS00548 2.47 expression: heart brain kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak010275|ak010275_1 riken full-length 
enriched library; clone:2400003o04 - mus musculus 
 
NM_053319_1 2.65 protein inhibitor of neuronal nitric oxide synthase pin; dynein; 
cytoplasmic; light peptide 
   
X61296_2 2.66 orf2 consensus sequence encoding endonuclease and reverse 
transcriptase minus rnaseh; unknown protein; orf 2; open 
reading frame 
  
RATTUS02304 2.87 expression: liver kidney strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak002802|ak002802_1 riken full-length 
enriched library; clone:0610038k03 - mus musculus 
 
U67995_1 4.54 stearyl-coa desaturase 2 
       
NM_013214_1 17.53 cytosolic peroxisome proliferator-induced acyl-coa thioesterase; 
hydrolase rbach; rlach1; acyl coenzyme a thioester 
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GENE ID FOLD DESCRIPTION 
 INCREASE  
 
NM_012793_1 2.07 guanidinoacetate methyltransferase precursor; gamt 
 
NM_031012_1 2.18 kidney zn-peptidase precursor; aminopeptidase m apm; anpep 
 
M35052_1 2.29 f-0-atpase subunit b precursor 
 
NM_021765_1 2.57 beta prime cop copb 
 
NM_012771_1 2.64 lysozyme lyz 
 
RATTUS03013 2.78 expression: kidney strains: wistar_kyoto trembl||q9jmg1 ; 
complete cds; clone:1-9 
 
RATTUS00582 2.80 expression: kidney heart strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak007386|ak007386_1 riken full-length 
enriched library; clone:1810008o21 - mus musculus 
 
NM_053021_1 3.50 testostrone-repressed prostate message 2 clu; clusterin; putative 
open reading frame; sulfated glycoprotein precursor; trpm-2 
 
NM_012992_1 4.57 nucleoplasmin-related protein nuclear protein b23 npm1; 
nucleolar; b23.1 
 
RATTUS01085 5.88 expression: liver brain heart strains: shrsp sprague_dawley 
wistar_kyoto gbp|ak014338|ak014338_1 riken full-length 
enriched library; clone:3230402m22 - mus musculus 
 
NM_017306_1 7.16 dodecenoyl-coenzyme a delta isomerase 3;2 trans-enoyl-
coenyme a isomerase dci; delta-3;delta-2-enoyl-coa; 3-2trans-
enoyl-coa 
 
RATTUS01484 13.43 expression: liver strains: shrsp wistar_kyoto 
gbp|m17440|m17440_1 c4a complement component c4a - mus 
musculus 
   
   
GENE ID FOLD DESCRIPTION 
 DECREASE  
   
NM_012615_1 1.98 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
NM_012615_1 2.05 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
NM_012615_1 2.08 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
NM_053792_1 2.08 selective lim binding factor; rat homolog slb; factor 
 
NM_031535_1 2.09 b cell lymphoma 2 like bcl2l; bcl-xbeta 
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NM_053598_1 2.10 diphosphoinositol polyphosphate phosphohydolase type ii nudt4 
 
D30804_1 2.13 proteasome subunit rc6-1 
 
NM_012615_1 2.16 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
NM_013059_1 2.18 tissue-nonspecific alp alkaline phosphatase alpl; precursor 
polypeptide aa -17 to 507 
 
NM_031774_1 2.29 rab acceptor 1 prenylated rabac1; pra1 
 
X67788_1 2.35 ezrin; p81 
 
NM_012497_1 2.54 aldolase c; fructose-biphosphate aldoc; c 
 
NM_032617_1 2.62 rab11b; member ras oncogene family rab11b; gtp-binding 
protein; gtp binding rab11-p24-b 
 
NM_012615_1 2.79 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
NM_031523_1 2.80 nerve growth factor; gamma polypeptide ngfg; kallikrein 
precursor; ps; s3; kal; 1; renal/pancreas/salivary klk1 
 
NM_017248_1 3.00 heterogeneous nuclear ribonucleoprotein a1 hnrpa1; helix 
destabilizing protein 
 
RATTUS03589 3.02 expression: brain strains: shrsp sprague_dawley trembl||q9nsn1 
hypothetical 110.4 kda protein fragment 
 
RATTUS01421 3.07 expression: heart brain kidney strains: shrsp wistar_kyoto 
trembl||q9jj97 brain cdna; clone mncb-0091 
 
AF273025_1 3.22 amino acid system n transporter 
 
M24930_1 3.27 mhc a-beta rt1.b-b-beta cell surface glycoprotein; class ii antigen 
b beta-chain rt1.bbeta; integral membrane protein rt1.b; a<beta>; 
rt1.b-1 
 
NM_031523_1 3.32 nerve growth factor; gamma polypeptide ngfg; kallikrein 
precursor; ps; s3; kal; 1; renal/pancreas/salivary klk1 
 
RATTUS00028 3.44 expression: heart brain strains: shrsp sprague_dawley 
wistar_kyoto gbp|ab055737|ab055737_1 nd1-l kelch family 
protein nd1-l - mus musculus 
 
NM_012615_1 3.49 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
 
S62903_1 3.60 genetic hypertension component sa 
 
RATTUS01155 3.64 expression: brain strains: shrsp sprague_dawley wistar_kyoto 
trembl||o08551 serine/arginine-rich protein specific kinase 2 ww 
domain binding protein 6 fragment 
 
NM_012615_1 3.65 ornithine decarboxylase ec 4.1.1.17; odc; ornitine odc1 
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NM_031763_1 3.98 platelet-activating factor acetylhydrolase beta subunit paf-ah 
beta pafah1b1 
 
NM_023102_1 5.35 casein kinase 1 gamma 2 isoform csnk1g2 
 
U67995_1 7.17 stearyl-coa desaturase 2 
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